|
G |
Arhgef26 |
Rho guanine nucleotide exchange factor 26 |
increases expression |
ISO |
Amphotericin B results in increased expression of ARHGEF26 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:27,107,263...27,236,336
Ensembl chr 2:27,107,318...27,236,672
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer] |
CTD |
PMID:16189267 |
|
NCBI chr 2:196,594,178...196,651,486
Ensembl chr 2:196,594,303...196,651,179
|
|
G |
Atg3 |
autophagy related 3 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of ATG3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:60,585,192...60,613,706
Ensembl chr11:60,585,171...60,613,718
|
|
G |
Casp3 |
caspase 3 |
increases expression |
ISO |
Amphotericin B results in increased expression of CASP3 protein |
CTD |
PMID:23988732 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
decreases expression |
EXP |
Amphotericin B results in decreased expression of CAT mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of CCR2 mRNA |
CTD |
PMID:20623750 |
|
|
|
G |
Clu |
clusterin |
affects expression |
EXP |
Amphotericin B affects the expression of CLU mRNA |
CTD |
PMID:20623750 |
|
NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
ISO |
Amphotericin B results in increased expression of EDNRB mRNA |
CTD |
PMID:20849824 |
|
NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
|
|
G |
Eno1 |
enolase 1 |
multiple interactions |
ISO |
Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of ENO1 mRNA]; Amphotericin B results in increased expression of and results in increased secretion of ENO1 protein |
CTD |
PMID:16189267 PMID:26259607 |
|
NCBI chr 5:167,288,223...167,299,610
Ensembl chr 5:167,288,223...167,299,609
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
Amphotericin B inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]] |
CTD |
PMID:16189267 |
|
NCBI chr 7:122,818,194...122,889,055
Ensembl chr 7:122,818,975...122,861,296
|
|
G |
Epo |
erythropoietin |
multiple interactions decreases expression |
ISO EXP |
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer]; Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] Amphotericin B results in decreased expression of EPO protein |
CTD |
PMID:697352 PMID:2299214 PMID:16189267 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Glod4 |
glyoxalase domain containing 4 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of GLOD4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr10:64,379,922...64,398,263
Ensembl chr10:64,379,921...64,398,294
|
|
G |
Gpr20 |
G protein-coupled receptor 20 |
increases expression |
ISO |
Amphotericin B results in increased expression of GPR20 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 7:114,943,675...114,953,977
Ensembl chr 7:114,944,282...114,945,344
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression multiple interactions |
EXP ISO |
Amphotericin B results in decreased expression of GSTP1 mRNA Amphotericin B inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:20623750 PMID:23769903 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of GSTT1 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases activity |
ISO |
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer]; Amphotericin B inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]]; Amphotericin B promotes the reaction [HIF1AN protein binds to and results in increased hydroxylation of and results in decreased activity of HIF1A protein] Amphotericin B results in decreased activity of HIF1A protein |
CTD |
PMID:16189267 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hif1an |
hypoxia inducible factor 1 subunit alpha inhibitor |
multiple interactions |
ISO |
Amphotericin B promotes the reaction [HIF1AN protein binds to and results in increased hydroxylation of and results in decreased activity of HIF1A protein] |
CTD |
PMID:16189267 |
|
NCBI chr 1:264,309,214...264,319,269
Ensembl chr 1:264,309,214...264,319,267
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
Amphotericin B results in increased expression of and results in increased secretion of HSPA8 protein |
CTD |
PMID:26259607 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Antimony Sodium Gluconate co-treated with Amphotericin B] results in increased expression of IFNG protein |
CTD |
PMID:17911647 PMID:29594315 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
increases expression |
ISO |
Amphotericin B results in increased expression of IFNGR1 |
CTD |
PMID:12803856 |
|
NCBI chr 1:15,062,380...15,080,815
Ensembl chr 1:15,062,432...15,080,907
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 9:80,154,230...80,166,813
Ensembl chr 9:80,150,211...80,167,033
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Antimony Sodium Gluconate co-treated with Amphotericin B] results in decreased expression of IL10 protein |
CTD |
PMID:17911647 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Amphotericin B results in increased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Kcnq4 |
potassium voltage-gated channel subfamily Q member 4 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of KCNQ4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 5:139,625,783...139,677,300
Ensembl chr 5:139,627,576...139,677,300
|
|
G |
Lsg1 |
large 60S subunit nuclear export GTPase 1 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of LSG1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:73,693,862...73,723,457
Ensembl chr11:73,693,814...73,723,501
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
Amphotericin B results in increased expression of MAP1LC3B protein |
CTD |
PMID:23988732 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Nprl2 |
NPR2-like, GATOR1 complex subunit |
decreases expression |
ISO |
Amphotericin B results in decreased expression of NPRL2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 8:116,297,950...116,301,123
Ensembl chr 8:116,297,950...116,301,122
|
|
G |
Nt5c2 |
5'-nucleotidase, cytosolic II |
increases expression |
ISO |
Amphotericin B results in increased expression of NT5C2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:266,652,966...266,782,935
Ensembl chr 1:266,659,519...266,782,910
|
|
G |
Paip1 |
poly(A) binding protein interacting protein 1 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of PAIP1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:52,300,921...52,328,212
Ensembl chr 2:52,301,798...52,328,205
|
|
G |
Pard3 |
par-3 family cell polarity regulator |
decreases expression |
ISO |
Amphotericin B results in decreased expression of PARD3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr19:60,017,746...60,580,628
Ensembl chr19:60,017,746...60,580,651
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
multiple interactions |
ISO |
Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of PGK1 mRNA] |
CTD |
PMID:16189267 |
|
NCBI chr X:77,263,399...77,279,373
Ensembl chr X:77,263,359...77,279,367
|
|
G |
Polm |
DNA polymerase mu |
increases expression |
ISO |
Amphotericin B results in increased expression of POLM mRNA |
CTD |
PMID:20849824 |
|
NCBI chr14:86,069,378...86,079,327
Ensembl chr14:86,069,016...86,078,954
|
|
G |
RT1-CE5 |
RT1 class I, locus CE5 |
increases expression |
ISO |
Amphotericin B results in increased expression of HLA-F mRNA |
CTD |
PMID:20849824 |
|
NCBI chr20:4,892,702...4,896,993
Ensembl chr20:4,892,702...4,896,991
|
|
G |
Runx3 |
RUNX family transcription factor 3 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of RUNX3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 5:153,507,093...153,531,137
Ensembl chr 5:153,507,093...153,531,137
|
|
G |
Slit1 |
slit guidance ligand 1 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of SLIT1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:260,843,481...260,992,366
Ensembl chr 1:260,843,483...260,992,366
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
affects expression |
EXP |
Amphotericin B affects the expression of SPP1 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Antimony Sodium Gluconate co-treated with Amphotericin B] results in decreased expression of TGFB1 protein |
CTD |
PMID:17911647 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
Amphotericin B results in increased expression of TNF mRNA |
CTD |
PMID:20623750 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
affects expression |
EXP |
Amphotericin B affects the expression of UGT1A9 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 9:95,161,157...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Usp36 |
ubiquitin specific peptidase 36 |
increases expression |
ISO |
Amphotericin B results in increased expression of USP36 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr10:107,292,828...107,324,355
Ensembl chr10:107,292,828...107,324,355
|
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
ISO |
methylamphotericin B results in increased expression of HAVCR1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
methylamphotericin B results in increased expression of LCN2 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
methylamphotericin B results in increased expression of SPP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
methylamphotericin B results in increased expression of TIMP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
|
G |
Hnmt |
histamine N-methyltransferase |
decreases activity |
ISO |
caspofungin results in decreased activity of HNMT protein |
CTD |
PMID:12921242 |
|
NCBI chr 3:905,111...937,038
Ensembl chr 3:904,765...937,102
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
Everolimus results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects stability affects response to substance multiple interactions |
ISO |
ABCB1A protein affects the stability of Everolimus ABCB1 polymorphism affects the susceptibility to Everolimus bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1A protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCB1A protein affects the metabolism of irinotecan] |
CTD |
PMID:24727322 PMID:27169792 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects stability multiple interactions |
ISO |
ABCB1B protein affects the stability of Everolimus bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1B protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCB1B protein affects the metabolism of irinotecan] |
CTD |
PMID:24727322 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects stability multiple interactions |
ISO |
ABCG2 protein affects the stability of Everolimus bis(4-nitrophenyl)phosphate inhibits the reaction [ABCG2 protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCG2 protein affects the metabolism of irinotecan] |
CTD |
PMID:24727322 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation decreases phosphorylation |
ISO |
Everolimus results in increased phosphorylation of AKT1 protein Everolimus results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16033851 PMID:22885370 PMID:23300809 PMID:28711525 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression multiple interactions |
ISO |
Everolimus results in decreased expression of BIRC5 protein Everolimus promotes the reaction [platycodin D results in decreased expression of BIRC5 protein]; navitoclax promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]; platycodin D promotes the reaction [Everolimus results in decreased expression of BIRC5 protein] |
CTD |
PMID:21601561 PMID:28711525 PMID:28947240 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Brd4 |
bromodomain containing 4 |
multiple interactions |
ISO |
[MYC protein results in decreased susceptibility to Everolimus] promotes the reaction [BRD4 protein binds to MYC gene] |
CTD |
PMID:25537515 |
|
NCBI chr 7:14,222,101...14,303,055
Ensembl chr 7:14,222,101...14,303,055
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
Everolimus results in increased cleavage of CASP3 protein |
CTD |
PMID:15940265 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
Everolimus results in decreased expression of CCNA2 protein |
CTD |
PMID:16856892 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
Everolimus results in decreased expression of CCND1 protein [letrozole co-treated with Everolimus] results in decreased expression of CCND1 protein |
CTD |
PMID:16033851 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions decreases expression |
ISO |
[letrozole co-treated with Everolimus] results in decreased expression of CCND2 protein Everolimus results in decreased expression of CCND2 protein |
CTD |
PMID:16033851 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Everolimus results in decreased expression of CCND3 protein |
CTD |
PMID:16856892 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
Everolimus results in increased expression of CDH1 protein |
CTD |
PMID:28258630 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases activity |
ISO |
Everolimus results in decreased activity of CES1 protein |
CTD |
PMID:24727322 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Ces2h |
carboxylesterase 2H |
decreases activity |
ISO |
Everolimus results in decreased activity of CES2 protein |
CTD |
PMID:24727322 |
|
NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression multiple interactions |
ISO |
Everolimus results in increased expression of EGFR mRNA; Everolimus results in increased expression of EGFR protein platycodin D inhibits the reaction [Everolimus results in increased expression of EGFR protein] |
CTD |
PMID:28711525 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
increases phosphorylation multiple interactions |
ISO |
Everolimus results in increased phosphorylation of EIF4E protein Everolimus inhibits the reaction [Estradiol results in decreased phosphorylation of EIF4E protein] |
CTD |
PMID:16033851 |
|
NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions decreases phosphorylation |
ISO |
[letrozole co-treated with Everolimus] results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein; Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein]; Everolimus promotes the reaction [platycodin D results in decreased phosphorylation of EIF4EBP1 protein]; Everolimus results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein; platycodin D promotes the reaction [Everolimus results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:16033851 PMID:16856892 PMID:16951235 PMID:21372221 PMID:28711525 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4 gamma, 1 |
multiple interactions |
ISO |
Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of EIF4G1 protein] |
CTD |
PMID:16033851 |
|
NCBI chr11:83,907,659...83,927,683
Ensembl chr11:83,908,109...83,926,524
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
Everolimus promotes the reaction [TNF protein results in increased expression of F3 protein] |
CTD |
PMID:19567381 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions increases expression |
ISO |
platycodin D inhibits the reaction [Everolimus results in increased expression of IGF1R protein] Everolimus results in increased expression of IGF1R mRNA; Everolimus results in increased expression of IGF1R protein |
CTD |
PMID:28711525 |
|
NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
Everolimus promotes the reaction [Tretinoin results in increased expression of ITGAM protein] |
CTD |
PMID:29743969 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Everolimus inhibits the reaction [4-cresol results in increased expression of MMP9 protein] |
CTD |
PMID:30910523 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions decreases activity |
ISO EXP |
[Everolimus co-treated with Y 27632] inhibits the reaction [4-cresol results in increased phosphorylation of MTOR protein]; [Letrozole co-treated with Everolimus] inhibits the reaction [Androstenedione affects the activity of MTOR protein]; Everolimus inhibits the reaction [4-cresol results in increased phosphorylation of MTOR protein]; Everolimus inhibits the reaction [Androstenedione affects the activity of MTOR protein]; Everolimus inhibits the reaction [Estradiol affects the activity of MTOR protein]; Everolimus inhibits the reaction [MTOR results in decreased susceptibility to Trabectedin] Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of MTOR protein]] Everolimus results in decreased activity of MTOR; Everolimus results in decreased activity of MTOR protein |
CTD |
PMID:16033851 PMID:20890178 PMID:21622721 PMID:24989011 PMID:30910523 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions decreases response to substance increases expression |
ISO |
[MYC protein results in decreased susceptibility to Everolimus] promotes the reaction [BRD4 protein binds to MYC gene] Everolimus results in increased expression of MYC protein |
CTD |
PMID:25537515 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of MTOR protein]]; Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of RPS6KB1 protein]] |
CTD |
PMID:24989011 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions decreases expression |
ISO |
Aspirin inhibits the reaction [Everolimus results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Everolimus results in decreased expression of NOS3 protein] |
CTD |
PMID:19520256 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
decreases activity |
ISO |
Everolimus results in decreased activity of NR1I3 protein |
CTD |
PMID:30203046 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[navitoclax co-treated with Everolimus] results in increased cleavage of PARP1 protein |
CTD |
PMID:28947240 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
Everolimus results in increased expression of PTGS2 mRNA; Everolimus results in increased expression of PTGS2 protein |
CTD |
PMID:15937522 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
decreases expression |
ISO |
Everolimus results in decreased expression of PTK2 protein modified form |
CTD |
PMID:28258630 |
|
NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions decreases phosphorylation |
ISO |
[letrozole co-treated with Everolimus] results in decreased phosphorylation of and affects the activity of RB1 protein; Everolimus results in decreased phosphorylation of and affects the activity of RB1 protein Everolimus results in decreased phosphorylation of RB1 protein |
CTD |
PMID:16033851 PMID:16856892 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rhoa |
ras homolog family member A |
decreases expression multiple interactions |
ISO |
Everolimus results in decreased expression of RHOA protein [Everolimus co-treated with Y 27632] inhibits the reaction [4-cresol results in increased expression of RHOA protein] |
CTD |
PMID:28258630 PMID:30910523 |
|
NCBI chr 8:117,082,440...117,116,244
Ensembl chr 8:117,106,576...117,116,167
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions decreases phosphorylation |
ISO |
[letrozole co-treated with Everolimus] results in decreased phosphorylation of RPS6 protein; Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of RPS6 protein] Everolimus results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:16033851 PMID:21372221 PMID:22885370 PMID:23151917 PMID:23300809 PMID:24386346 |
|
NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
EXP ISO |
Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of RPS6KB1 protein]] Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of RPS6KB1 protein]; Everolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:16033851 PMID:19567381 PMID:24989011 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
Aspirin inhibits the reaction [Everolimus results in decreased expression of SIRT1 protein]; cilostazol inhibits the reaction [Everolimus results in decreased expression of SIRT1 protein] |
CTD |
PMID:19520256 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
decreases expression |
ISO |
Everolimus results in decreased expression of SRC protein modified form |
CTD |
PMID:28258630 |
|
NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Everolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Everolimus promotes the reaction [TNF protein results in increased expression of F3 protein] |
CTD |
PMID:19567381 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
Everolimus results in decreased expression of VIM protein |
CTD |
PMID:28258630 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
fumagillin inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 mRNA] |
CTD |
PMID:15682466 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Metap1 |
methionyl aminopeptidase 1 |
decreases activity multiple interactions |
ISO |
fumagillin results in decreased activity of METAP1 protein [fumagillin results in decreased activity of [METAP1 protein co-treated with METAP2 protein]] which results in decreased metabolism of YWHAG protein |
CTD |
PMID:14534293 |
|
NCBI chr 2:243,744,620...243,777,673
Ensembl chr 2:243,744,620...243,777,673
|
|
G |
Metap2 |
methionyl aminopeptidase 2 |
multiple interactions decreases activity |
EXP ISO |
fumagillin promotes the reaction [Diethylnitrosamine results in increased expression of METAP2 mRNA] fumagillin results in decreased activity of METAP2 protein [fumagillin results in decreased activity of [METAP1 protein co-treated with METAP2 protein]] which results in decreased metabolism of YWHAG protein |
CTD |
PMID:14534293 PMID:15516829 PMID:15682466 |
|
NCBI chr 7:34,762,241...34,789,456
Ensembl chr 7:34,762,231...34,789,479
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
EXP |
fumagillin inhibits the reaction [Diethylnitrosamine results in increased activity of TERT protein]; fumagillin inhibits the reaction [Diethylnitrosamine results in increased expression of TERT mRNA] |
CTD |
PMID:15682466 |
|
NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
|
|
G |
Ywhag |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma |
multiple interactions |
ISO |
[fumagillin results in decreased activity of [METAP1 protein co-treated with METAP2 protein]] which results in decreased metabolism of YWHAG protein |
CTD |
PMID:14534293 |
|
NCBI chr12:23,789,547...23,817,884
Ensembl chr12:23,789,638...23,817,883
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
Griseofulvin results in increased expression of ABCB1A mRNA |
CTD |
PMID:8707270 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression |
ISO |
Griseofulvin results in increased expression of ABCB4 mRNA |
CTD |
PMID:8707270 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
decreases expression |
ISO |
Griseofulvin results in decreased expression of ADRB3 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr16:69,003,541...69,006,632
Ensembl chr16:69,003,868...69,006,632
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
affects expression multiple interactions increases activity increases expression |
ISO |
Griseofulvin affects the expression of ALAS1 mRNA 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Griseofulvin results in increased activity of ALAS1 protein]; [Ascorbic Acid co-treated with 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid] inhibits the reaction [Griseofulvin results in increased activity of ALAS1 protein]; Ascorbic Acid inhibits the reaction [Griseofulvin results in increased activity of ALAS1 protein]; Melatonin inhibits the reaction [Griseofulvin results in increased activity of ALAS1 protein] Griseofulvin results in increased expression of ALAS1 mRNA |
CTD |
PMID:10215191 PMID:12735108 PMID:15793285 PMID:24523661 |
|
NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177
|
|
G |
Anxa2 |
annexin A2 |
increases expression |
ISO |
Griseofulvin results in increased expression of ANXA2 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
|
|
G |
Anxa3 |
annexin A3 |
affects expression |
ISO |
Griseofulvin affects the expression of ANXA3 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr14:14,371,921...14,426,503
Ensembl chr14:14,364,008...14,426,437
|
|
G |
Anxa5 |
annexin A5 |
increases expression |
ISO |
Griseofulvin results in increased expression of ANXA5 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 2:123,162,477...123,194,730
Ensembl chr 2:123,162,461...123,193,130
|
|
G |
Anxa6 |
annexin A6 |
increases expression |
ISO |
Griseofulvin results in increased expression of ANXA6 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr10:40,320,581...40,375,605
Ensembl chr10:40,320,581...40,375,605
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
Griseofulvin results in increased expression of AREG protein |
CTD |
PMID:19267999 |
|
NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
|
|
G |
Btc |
betacellulin |
increases expression |
ISO |
Griseofulvin results in increased expression of BTC protein |
CTD |
PMID:19267999 |
|
NCBI chr14:18,231,854...18,270,621
Ensembl chr14:18,231,860...18,272,484
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage |
ISO |
Griseofulvin results in increased activity of CASP3 protein Griseofulvin results in increased cleavage of CASP3 protein |
CTD |
PMID:23329179 PMID:25412316 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Griseofulvin results in increased activity of CASP9 protein |
CTD |
PMID:23329179 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cbr1 |
carbonyl reductase 1 |
affects expression |
ISO |
Griseofulvin affects the expression of CBR1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr11:33,813,041...33,815,418
Ensembl chr11:33,845,463...33,847,793
|
|
G |
Cd14 |
CD14 molecule |
affects expression |
ISO |
Griseofulvin affects the expression of CD14 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cd24 |
CD24 molecule |
affects expression |
ISO |
Griseofulvin affects the expression of CD24A mRNA |
CTD |
PMID:12735108 |
|
NCBI chr20:48,335,540...48,340,847
Ensembl chr20:48,335,540...48,340,846
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Griseofulvin results in increased expression of COL1A1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
increases expression |
ISO |
Griseofulvin results in increased expression of COL3A1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
affects expression |
ISO |
Griseofulvin affects the expression of COL4A1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
|
|
G |
Cstb |
cystatin B |
increases expression |
ISO |
Griseofulvin results in increased expression of CSTB mRNA |
CTD |
PMID:12735108 |
|
NCBI chr20:10,966,357...10,968,399
Ensembl chr20:10,966,331...10,968,432
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects expression multiple interactions |
ISO |
Griseofulvin affects the expression of CYP1A2 mRNA Griseofulvin promotes the reaction [CYP1A2 protein affects the metabolism of Theophylline] |
CTD |
PMID:9029748 PMID:12735108 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
increases activity increases expression |
ISO |
Griseofulvin results in increased activity of CYP2A5 protein Griseofulvin results in increased expression of CYP2A5 mRNA; Griseofulvin results in increased expression of CYP2A5 protein |
CTD |
PMID:7543189 PMID:9007836 PMID:9698299 PMID:11038160 |
|
NCBI chr 1:83,653,248...83,662,118
Ensembl chr 1:83,653,234...83,766,484
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
affects expression |
ISO |
Griseofulvin affects the expression of CYP2B10 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
affects expression |
ISO |
Griseofulvin affects the expression of CYP2B13 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 1:83,103,925...83,119,578
Ensembl chr 1:83,103,925...83,119,193
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
affects expression |
ISO |
Griseofulvin affects the expression of CYP2B9 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects expression |
ISO |
Griseofulvin affects the expression of CYP2C29 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases expression affects expression |
ISO |
Griseofulvin results in increased expression of CYP3A4 mRNA; Griseofulvin results in increased expression of CYP3A4 protein Griseofulvin affects the expression of CYP3A11 mRNA |
CTD |
PMID:12735108 PMID:18505790 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression |
ISO |
Griseofulvin results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
|
|
G |
Eln |
elastin |
affects expression |
ISO |
Griseofulvin affects the expression of ELN mRNA |
CTD |
PMID:12735108 |
|
NCBI chr12:24,978,478...25,021,864
Ensembl chr12:24,978,483...25,021,863
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Griseofulvin results in increased expression of EREG protein |
CTD |
PMID:19267999 |
|
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
decreases expression |
ISO |
Griseofulvin results in decreased expression of FABP1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fech |
ferrochelatase |
decreases activity increases expression multiple interactions |
ISO |
Griseofulvin results in decreased activity of FECH protein Griseofulvin results in increased expression of FECH mRNA [Griseofulvin results in decreased activity of FECH protein] which results in decreased uptake of Iron; heme arginate inhibits the reaction [[Griseofulvin results in decreased activity of FECH protein] which results in decreased uptake of Iron] |
CTD |
PMID:10215191 PMID:15078340 |
|
NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192
|
|
G |
Fstl1 |
follistatin-like 1 |
affects expression |
ISO |
Griseofulvin affects the expression of FSTL1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr11:65,791,196...65,845,721
Ensembl chr11:65,782,567...65,845,418
|
|
G |
G0s2 |
G0/G1switch 2 |
decreases expression |
ISO |
Griseofulvin results in decreased expression of G0S2 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr13:112,004,140...112,005,052
Ensembl chr13:112,004,140...112,005,052
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
affects expression |
ISO |
Griseofulvin affects the expression of GADD45B mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases expression |
ISO |
Griseofulvin results in increased expression of and results in increased localization of GJA1 protein Griseofulvin results in increased expression of GJA1 mRNA |
CTD |
PMID:23329179 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
affects expression |
ISO |
Griseofulvin affects the expression of GSTM2 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases activity increases expression |
ISO |
Griseofulvin results in increased activity of HMOX1 protein Griseofulvin results in increased expression of HMOX1 mRNA; Griseofulvin results in increased expression of HMOX1 protein |
CTD |
PMID:10215191 PMID:15793285 PMID:16309571 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Ier3 |
immediate early response 3 |
affects expression |
ISO |
Griseofulvin affects the expression of IER3 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases expression |
ISO |
Griseofulvin results in decreased expression of IGF1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Igfals |
insulin-like growth factor binding protein, acid labile subunit |
decreases expression |
ISO |
Griseofulvin results in decreased expression of IGFALS mRNA |
CTD |
PMID:12735108 |
|
NCBI chr10:14,240,308...14,243,554
Ensembl chr10:14,240,219...14,243,597
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
affects expression |
ISO |
Griseofulvin affects the expression of IGFBP2 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 9:80,118,029...80,144,804
Ensembl chr 9:80,118,029...80,144,789
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
Griseofulvin inhibits the reaction [IL1A protein results in increased expression of VCAM1 protein] |
CTD |
PMID:11367519 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Inhbc |
inhibin subunit beta C |
decreases expression |
ISO |
Griseofulvin results in decreased expression of INHBC mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 7:70,648,005...70,661,475
Ensembl chr 7:70,646,519...70,661,891
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
affects expression |
ISO |
Griseofulvin affects the expression of IQGAP1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 1:142,525,041...142,615,673
Ensembl chr 1:142,525,046...142,615,673
|
|
G |
Itgb2 |
integrin subunit beta 2 |
affects expression |
ISO |
Griseofulvin affects the expression of ITGB2 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr20:11,777,773...11,815,647
Ensembl chr20:11,777,783...11,815,647
|
|
G |
Krt18 |
keratin 18 |
multiple interactions increases expression decreases response to substance |
ISO |
Griseofulvin promotes the reaction [KRT18 protein binds to KRT18 protein] Griseofulvin results in increased expression of KRT18 mRNA; Griseofulvin results in increased expression of KRT18 protein KRT18 protein results in decreased susceptibility to Griseofulvin |
CTD |
PMID:7504119 PMID:8770877 PMID:10952237 PMID:12388748 |
|
NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
|
|
G |
Krt8 |
keratin 8 |
increases expression increases phosphorylation |
ISO |
Griseofulvin results in increased expression of KRT8 mRNA; Griseofulvin results in increased expression of KRT8 protein Griseofulvin results in increased phosphorylation of KRT8 protein |
CTD |
PMID:7504119 PMID:10952237 PMID:12735108 PMID:20643122 |
|
NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
|
|
G |
Lamb1 |
laminin subunit beta 1 |
decreases expression |
ISO |
Griseofulvin results in decreased expression of LAMB1 protein |
CTD |
PMID:1573853 |
|
NCBI chr 6:50,528,796...50,596,593
Ensembl chr 6:50,528,823...50,596,079
|
|
G |
Lamb2 |
laminin subunit beta 2 |
decreases expression increases expression |
ISO |
Griseofulvin results in decreased expression of LAMB2 protein Griseofulvin results in increased expression of LAMB2 mRNA |
CTD |
PMID:1573853 |
|
NCBI chr 8:117,268,335...117,280,517
Ensembl chr 8:117,268,337...117,280,517
|
|
G |
Lilrb4 |
leukocyte immunoglobulin like receptor B4 |
affects expression |
ISO |
Griseofulvin affects the expression of LILRB4 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 1:73,393,854...73,399,448
Ensembl chr 1:73,393,850...73,399,579
|
|
G |
Lpl |
lipoprotein lipase |
affects expression |
ISO |
Griseofulvin affects the expression of LPL mRNA |
CTD |
PMID:12735108 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Ly6d |
lymphocyte antigen 6 family member D |
increases expression |
ISO |
Griseofulvin results in increased expression of LY6D mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 7:115,993,304...115,994,812
Ensembl chr 7:115,993,301...115,994,783
|
|
G |
Mapt |
microtubule-associated protein tau |
increases expression |
ISO |
Griseofulvin results in increased expression of MAPT mRNA; Griseofulvin results in increased expression of MAPT mRNA alternative form; Griseofulvin results in increased expression of MAPT protein |
CTD |
PMID:10051481 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
ISO |
Griseofulvin results in increased expression of MT1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Npdc1 |
neural proliferation, differentiation and control, 1 |
affects expression |
ISO |
Griseofulvin affects the expression of NPDC1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 3:2,624,231...2,630,672
Ensembl chr 3:2,625,015...2,630,670
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Griseofulvin results in increased expression of NQO1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
Griseofulvin inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Papss2 |
3'-phosphoadenosine 5'-phosphosulfate synthase 2 |
affects expression |
ISO |
Griseofulvin affects the expression of PAPSS2 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 1:251,145,264...251,230,716
Ensembl chr 1:251,145,253...251,230,715
|
|
G |
Pf4 |
platelet factor 4 |
affects expression |
ISO |
Griseofulvin affects the expression of PF4 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr14:18,848,549...18,849,258
Ensembl chr14:18,848,549...18,849,258
|
|
G |
Por |
cytochrome p450 oxidoreductase |
affects expression |
ISO |
Griseofulvin affects the expression of POR mRNA |
CTD |
PMID:12735108 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
Griseofulvin results in decreased expression of PPARA mRNA |
CTD |
PMID:9548566 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression |
ISO |
Griseofulvin results in increased expression of PPARD mRNA |
CTD |
PMID:9548566 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
Griseofulvin results in increased expression of PPARG mRNA |
CTD |
PMID:9548566 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppl |
periplakin |
affects expression |
ISO |
Griseofulvin affects the expression of PPL mRNA |
CTD |
PMID:12735108 |
|
NCBI chr10:10,644,572...10,690,223
Ensembl chr10:10,644,572...10,690,223
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases expression |
ISO |
Griseofulvin results in increased expression of RARA mRNA |
CTD |
PMID:9548566 |
|
NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
|
|
G |
Rarb |
retinoic acid receptor, beta |
increases expression |
ISO |
Griseofulvin results in increased expression of RARB mRNA |
CTD |
PMID:9548566 |
|
NCBI chr15:9,915,223...10,262,599
Ensembl chr15:10,120,206...10,262,599
|
|
G |
Rarg |
retinoic acid receptor, gamma |
increases expression |
ISO |
Griseofulvin results in increased expression of RARG mRNA |
CTD |
PMID:9548566 |
|
NCBI chr 7:143,840,739...143,863,206
Ensembl chr 7:143,839,980...143,863,186
|
|
G |
Rxra |
retinoid X receptor alpha |
decreases expression |
ISO |
Griseofulvin results in decreased expression of RXRA mRNA |
CTD |
PMID:9548566 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Rxrg |
retinoid X receptor gamma |
decreases expression |
ISO |
Griseofulvin results in decreased expression of RXRG mRNA |
CTD |
PMID:9548566 |
|
NCBI chr13:85,818,473...85,868,555
Ensembl chr13:85,818,427...85,868,552
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
increases expression |
ISO |
Griseofulvin results in increased expression of S100A6 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 2:190,007,013...190,008,512
Ensembl chr 2:190,007,216...190,008,511
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
affects expression |
ISO |
Griseofulvin affects the expression of SCD2 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 1:264,059,374...264,072,433
Ensembl chr 1:264,059,374...264,072,433
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
Griseofulvin inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:11367519 |
|
NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341
|
|
G |
Sell |
selectin L |
decreases expression |
ISO |
Griseofulvin results in decreased expression of SELL protein |
CTD |
PMID:11367519 |
|
NCBI chr13:82,369,820...82,387,774
Ensembl chr13:82,369,493...82,387,631
|
|
G |
Soat1 |
sterol O-acyltransferase 1 |
affects expression |
ISO |
Griseofulvin affects the expression of SOAT1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr13:74,035,258...74,077,759
Ensembl chr13:74,035,080...74,077,783
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
affects expression |
ISO |
Griseofulvin affects the expression of SPP1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Tgm2 |
transglutaminase 2 |
affects expression |
ISO |
Griseofulvin affects the expression of TGM2 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 3:154,597,165...154,627,257
Ensembl chr 3:154,597,168...154,627,257
|
|
G |
Tm4sf4 |
transmembrane 4 L six family member 4 |
affects expression |
ISO |
Griseofulvin affects the expression of TM4SF4 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 2:147,532,032...147,547,254
Ensembl chr 2:147,496,229...147,547,252
|
|
G |
Tmsb10 |
thymosin, beta 10 |
affects expression |
ISO |
Griseofulvin affects the expression of TMSB10 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 4:100,882,216...100,883,303
Ensembl chr 4:100,882,216...100,883,275
|
|
G |
Tmsb4x |
thymosin beta 4, X-linked |
affects expression |
ISO |
Griseofulvin affects the expression of TMSB4X mRNA |
CTD |
PMID:12735108 |
|
NCBI chr X:28,593,405...28,617,267
Ensembl chr X:28,593,405...28,595,395
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Griseofulvin inhibits the reaction [TNF protein results in increased expression of SELE protein]; Griseofulvin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; Griseofulvin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Paclitaxel inhibits the reaction [Griseofulvin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; Paclitaxel inhibits the reaction [Griseofulvin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] |
CTD |
PMID:11154858 PMID:11367519 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Ugdh |
UDP-glucose 6-dehydrogenase |
affects expression |
ISO |
Griseofulvin affects the expression of UGDH mRNA |
CTD |
PMID:12735108 |
|
NCBI chr14:44,479,614...44,502,845
Ensembl chr14:44,479,614...44,502,845
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
affects expression |
ISO |
Griseofulvin affects the expression of UGT1A1 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
affects expression multiple interactions |
ISO |
Griseofulvin affects the expression of VCAM1 mRNA Griseofulvin inhibits the reaction [IL1A protein results in increased expression of VCAM1 protein]; Griseofulvin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; Griseofulvin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Paclitaxel inhibits the reaction [Griseofulvin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; Paclitaxel inhibits the reaction [Griseofulvin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] |
CTD |
PMID:11154858 PMID:11367519 PMID:12735108 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
G |
Vcl |
vinculin |
affects localization |
ISO |
Griseofulvin affects the localization of VCL protein |
CTD |
PMID:25412316 |
|
NCBI chr15:3,455,211...3,544,738
Ensembl chr15:3,455,211...3,544,702
|
|
G |
Wnt3a |
Wnt family member 3A |
affects expression |
ISO |
Griseofulvin affects the expression of WNT3A mRNA |
CTD |
PMID:12735108 |
|
NCBI chr10:45,598,898...45,643,151
Ensembl chr10:45,598,912...45,638,035
|
|
G |
Ybx3 |
Y box binding protein 3 |
affects expression |
ISO |
Griseofulvin affects the expression of YBX3 mRNA |
CTD |
PMID:12735108 |
|
NCBI chr 4:165,606,819...165,630,041
Ensembl chr 4:165,606,819...165,630,118
|
|
|
G |
Clu |
clusterin |
increases expression |
ISO |
Natamycin results in increased expression of CLU mRNA |
CTD |
PMID:22863853 |
|
NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
|
|
G |
Cp |
ceruloplasmin |
increases expression |
ISO |
Natamycin results in increased expression of CP mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Fga |
fibrinogen alpha chain |
increases expression |
ISO |
Natamycin results in increased expression of FGA mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 2:181,997,562...182,013,726
Ensembl chr 2:182,006,242...182,013,763
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression |
ISO |
Natamycin results in increased expression of FGG mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 2:181,987,080...181,994,523
Ensembl chr 2:181,987,217...181,994,514
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
ISO |
Natamycin results in increased expression of HAVCR1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
|
|
G |
Krt19 |
keratin 19 |
increases expression |
ISO |
Natamycin results in increased expression of KRT19 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr10:88,055,843...88,060,560
Ensembl chr10:88,055,841...88,060,561
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
Natamycin results in increased expression of LCN2 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
Natamycin results in increased expression of SPP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
Natamycin results in increased expression of TIMP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Nystatin inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:12614848 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Nystatin inhibits the reaction [resveratrol affects the localization of CASP8 protein] |
CTD |
PMID:12902349 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions |
ISO |
Nystatin inhibits the reaction [Quercetin affects the localization of CAV1 protein] |
CTD |
PMID:17876056 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Cd40 |
CD40 molecule |
increases expression |
ISO |
Nystatin results in increased expression of CD40 protein |
CTD |
PMID:16374455 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Cd80 |
Cd80 molecule |
increases expression |
ISO |
Nystatin results in increased expression of CD80 protein |
CTD |
PMID:16374455 |
|
NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
Nystatin results in increased expression of CD86 protein |
CTD |
PMID:16374455 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Clu |
clusterin |
increases expression |
ISO |
Nystatin results in increased expression of CLU mRNA |
CTD |
PMID:22863853 |
|
NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
|
|
G |
Cp |
ceruloplasmin |
increases expression |
ISO |
Nystatin results in increased expression of CP mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
ISO |
Nystatin inhibits the reaction [resveratrol affects the localization of FADD protein] |
CTD |
PMID:12902349 |
|
NCBI chr 1:217,746,176...217,748,581
Ensembl chr 1:217,742,929...217,748,628
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
Nystatin inhibits the reaction [resveratrol affects the localization of FAS protein] |
CTD |
PMID:12902349 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fga |
fibrinogen alpha chain |
increases expression |
ISO |
Nystatin results in increased expression of FGA mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 2:181,997,562...182,013,726
Ensembl chr 2:182,006,242...182,013,763
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression |
ISO |
Nystatin results in increased expression of FGG mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 2:181,987,080...181,994,523
Ensembl chr 2:181,987,217...181,994,514
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
ISO |
Nystatin results in increased expression of HAVCR1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
Nystatin results in increased expression of ICAM1 protein |
CTD |
PMID:16374455 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Nystatin results in increased expression of IL1B mRNA; Nystatin results in increased expression of IL1B protein |
CTD |
PMID:16374455 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Nystatin results in increased expression of IL6 protein |
CTD |
PMID:16374455 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Krt18 |
keratin 18 |
increases expression |
ISO |
Nystatin results in increased expression of KRT18 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
|
|
G |
Krt19 |
keratin 19 |
increases expression |
ISO |
Nystatin results in increased expression of KRT19 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr10:88,055,843...88,060,560
Ensembl chr10:88,055,841...88,060,561
|
|
G |
Krt8 |
keratin 8 |
increases expression |
ISO |
Nystatin results in increased expression of KRT8 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
Nystatin results in increased expression of LCN2 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
Nystatin inhibits the reaction [4-ethylphenol results in increased phosphorylation of MAPK1 protein]; Nystatin inhibits the reaction [4-propylphenol results in increased phosphorylation of MAPK1 protein]; Nystatin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; Nystatin inhibits the reaction [Diethylstilbestrol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Nystatin inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Nystatin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK1 protein]; Nystatin inhibits the reaction [Estriol results in increased phosphorylation of MAPK1 protein]; Nystatin inhibits the reaction [Estrone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15072920 PMID:22230296 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Nystatin inhibits the reaction [4-ethylphenol results in increased phosphorylation of MAPK3 protein]; Nystatin inhibits the reaction [4-propylphenol results in increased phosphorylation of MAPK3 protein]; Nystatin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Nystatin inhibits the reaction [Diethylstilbestrol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Nystatin inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Nystatin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; Nystatin inhibits the reaction [Estriol results in increased phosphorylation of MAPK3 protein]; Nystatin inhibits the reaction [Estrone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15072920 PMID:22230296 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Prnp |
prion protein |
multiple interactions |
ISO |
Nystatin inhibits the reaction [Copper Sulfate results in increased uptake of and affects the localization of PRNP protein] |
CTD |
PMID:11994310 |
|
NCBI chr 3:124,515,917...124,531,320
Ensembl chr 3:124,515,978...124,531,316
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
increases activity |
ISO |
Nystatin results in increased activity of REL protein |
CTD |
PMID:16374455 |
|
NCBI chr14:108,490,794...108,517,582
Ensembl chr14:108,491,069...108,509,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases activity |
ISO |
Nystatin results in increased activity of RELA protein |
CTD |
PMID:16374455 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
Nystatin results in increased expression of SPP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
Nystatin results in increased expression of TIMP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
Nystatin inhibits the reaction [Quercetin affects the localization of TNFRSF10A protein] |
CTD |
PMID:17876056 |
|
NCBI chr15:51,433,853...51,464,215
|
|
G |
Vim |
vimentin |
increases expression |
ISO |
Nystatin results in increased expression of VIM mRNA |
CTD |
PMID:22863853 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation decreases response to substance |
ISO |
OSU 03012 results in decreased phosphorylation of AKT1 protein AKT1 protein modified form results in decreased susceptibility to OSU 03012 |
CTD |
PMID:15205346 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase-1 |
multiple interactions decreases response to substance |
ISO |
OSU 03012 binds to and results in decreased activity of PDPK1 protein PDPK1 protein modified form results in decreased susceptibility to OSU 03012 |
CTD |
PMID:15205346 |
|
NCBI chr10:13,446,373...13,525,248
Ensembl chr10:13,451,624...13,515,448
|
|
|
G |
A2m |
alpha-2-macroglobulin |
increases expression |
EXP |
Sirolimus results in increased expression of A2M mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 4:154,309,426...154,359,138
Ensembl chr 4:154,309,426...154,359,137
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression |
ISO EXP |
[Sirolimus co-treated with Cyclosporine] results in decreased expression of ABCA1 protein; [Sirolimus co-treated with Tacrolimus] results in increased expression of ABCA1 protein Sirolimus results in increased expression of ABCA1 mRNA |
CTD |
PMID:17016853 PMID:21865292 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects metabolic processing affects transport |
ISO |
ABCB1 protein affects the metabolism of Sirolimus ABCB1 protein affects the transport of Sirolimus |
CTD |
PMID:15707415 PMID:15760093 PMID:15964407 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
EXP |
Sirolimus results in decreased expression of ABCC2 mRNA |
CTD |
PMID:11589784 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
decreases expression |
EXP |
Sirolimus results in decreased expression of ABCC8 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:102,110,708...102,191,287
Ensembl chr 1:102,110,708...102,191,287
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]] |
CTD |
PMID:25045214 |
|
NCBI chr 9:73,833,368...73,871,857
Ensembl chr 9:73,833,388...73,871,888
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]] |
CTD |
PMID:25045214 |
|
NCBI chr 2:260,124,418...260,148,589
Ensembl chr 2:260,124,418...260,148,589
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
decreases expression |
EXP |
Sirolimus results in decreased expression of ACE2 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr X:32,050,734...32,095,860
Ensembl chr X:32,049,931...32,096,016
|
|
G |
Acer2 |
alkaline ceramidase 2 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of ACER2 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 5:105,230,540...105,279,732
Ensembl chr 5:105,230,580...105,279,731
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
[Sirolimus co-treated with IGF1 protein] results in increased expression of ACTA2 protein |
CTD |
PMID:17908691 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Actb |
actin, beta |
increases expression multiple interactions |
ISO |
Sirolimus results in increased expression of ACTB mRNA [Sirolimus binds to FKBP1A protein] which results in increased expression of ACTB mRNA |
CTD |
PMID:7503980 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [AGT protein affects the localization of Calcium] |
CTD |
PMID:21613610 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
decreases expression multiple interactions |
EXP ISO |
Sirolimus results in decreased expression of AIFM1 protein [7-hydroxystaurosporine co-treated with Sirolimus] affects the localization of AIFM1 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] affects the localization of AIFM1 protein] |
CTD |
PMID:15767555 PMID:16497721 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions affects phosphorylation increases phosphorylation decreases phosphorylation |
ISO EXP |
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [Sirolimus co-treated with Arsenic Trioxide] results in decreased phosphorylation of AKT1 protein; Arsenic Trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]; Cisplatin inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Tretinoin results in increased phosphorylation of AKT1 protein] Sirolimus affects the phosphorylation of AKT1 protein resveratrol inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]] [Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein; Sirolimus results in increased phosphorylation of AKT1 protein Sirolimus results in decreased phosphorylation of AKT1 protein [Sirolimus co-treated with Resveratrol] promotes the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Resveratrol results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:15806154 PMID:18495876 PMID:18622747 PMID:19176369 PMID:21092744 PMID:21976531 PMID:23000059 PMID:24299490 PMID:24304514 PMID:24392034 PMID:25597859 PMID:25758096 PMID:26282490 PMID:26369790 PMID:28108221 PMID:28342888 PMID:30905858 PMID:31499194 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Akt1s1 |
AKT1 substrate 1 |
multiple interactions |
ISO EXP |
[Sirolimus co-treated with resveratrol] results in decreased phosphorylation of AKT1S1 protein; resveratrol inhibits the reaction [Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein] [resveratrol co-treated with Sirolimus] results in decreased phosphorylation of AKT1S1 protein |
CTD |
PMID:24304514 |
|
NCBI chr 1:100,845,443...100,851,961
Ensembl chr 1:100,845,563...100,851,960
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
[Sirolimus results in increased activity of AKT2 protein] which results in increased expression of CALD1 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of MYH11 protein; Sirolimus results in increased phosphorylation of and results in increased activity of AKT2 protein |
CTD |
PMID:17908691 |
|
NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
|
|
G |
Angptl6 |
angiopoietin-like 6 |
increases expression |
EXP |
Sirolimus results in increased expression of ANGPTL6 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 8:21,895,523...21,902,002
Ensembl chr 8:21,895,524...21,901,829
|
|
G |
Aopep |
aminopeptidase O |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of AOPEP mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr17:507,389...825,062
Ensembl chr17:507,377...821,582
|
|
G |
Apod |
apolipoprotein D |
affects localization |
ISO |
Sirolimus affects the localization of APOD protein |
CTD |
PMID:28182653 |
|
NCBI chr11:72,705,204...72,726,263
Ensembl chr11:72,705,129...72,726,301
|
|
G |
App |
amyloid beta precursor protein |
decreases expression increases expression |
ISO |
Sirolimus results in decreased expression of APP protein modified form Sirolimus results in increased expression of APP protein modified form |
CTD |
PMID:20542014 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Aqp2 |
aquaporin 2 |
multiple interactions decreases expression |
EXP |
rosiglitazone inhibits the reaction [Sirolimus results in decreased expression of AQP2 protein] |
CTD |
PMID:19656910 |
|
NCBI chr 7:141,237,802...141,242,837
Ensembl chr 7:141,237,768...141,245,165
|
|
G |
Ar |
androgen receptor |
multiple interactions increases expression increases activity |
ISO |
[Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; bicalutamide inhibits the reaction [Sirolimus results in increased activity of AR protein]; RPTOR protein inhibits the reaction [Sirolimus results in increased activity of AR protein]; Sirolimus affects the reaction [Testosterone results in increased expression of AR protein]; Sirolimus promotes the reaction [Dihydrotestosterone affects the expression of AR protein] Sirolimus results in increased expression of AR protein |
CTD |
PMID:18776922 PMID:21036700 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in increased expression of ASNS mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of ATF3 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO EXP |
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of ATF4] Sirolimus inhibits the reaction [cadmium acetate results in increased expression of ATF4 protein] |
CTD |
PMID:24057571 PMID:29870746 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atg4a |
autophagy related 4A, cysteine peptidase |
increases expression |
ISO |
Sirolimus results in increased expression of ATG4A mRNA |
CTD |
PMID:21681844 |
|
NCBI chr X:112,328,907...112,403,157
|
|
G |
Atg4b |
autophagy related 4B, cysteine peptidase |
increases expression |
ISO |
Sirolimus results in increased expression of ATG4B mRNA |
CTD |
PMID:21681844 |
|
NCBI chr 9:100,888,457...100,920,123
Ensembl chr 9:100,888,501...100,918,637
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases expression |
ISO EXP |
[Sirolimus co-treated with TNF protein] results in increased expression of ATG5 mRNA; ATG5 protein affects the reaction [Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]] Sirolimus results in increased expression of ATG5 protein Sirolimus results in increased expression of ATG5 mRNA; Sirolimus results in increased expression of ATG5 protein [Sirolimus co-treated with cadmium acetate] results in increased expression of ATG5 mRNA; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of ATG5 protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]] |
CTD |
PMID:19682553 PMID:29128638 PMID:29505745 PMID:29870746 PMID:30338810 PMID:30611790 PMID:31676321 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
[Sirolimus co-treated with TNF protein] results in increased expression of ATG7 mRNA |
CTD |
PMID:31676321 |
|
NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
|
|
G |
Aurkb |
aurora kinase B |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of AURKB mRNA |
CTD |
PMID:19016759 |
|
NCBI chr10:55,625,860...55,632,399
Ensembl chr10:55,626,741...55,634,991
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in increased expression of BAD mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects localization increases expression multiple interactions |
ISO |
Sirolimus affects the localization of BAX protein Sirolimus results in increased expression of BAX mRNA; Sirolimus results in increased expression of BAX protein [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX protein [Curcumin co-treated with Sirolimus] results in increased expression of BAX; Sirolimus inhibits the reaction [rebamipide results in decreased expression of BAX protein] |
CTD |
PMID:11602639 PMID:15782132 PMID:19373661 PMID:19922502 PMID:29054700 PMID:30905858 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
[[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of BBC3 protein; Sirolimus promotes the reaction [TP53 protein results in increased expression of BBC3 protein] |
CTD |
PMID:19560264 PMID:20686837 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions affects expression decreases expression |
ISO EXP |
[Curcumin co-treated with Sirolimus] results in decreased expression of BCL2; Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BCL2 protein]; Sirolimus inhibits the reaction [rebamipide results in increased expression of BCL2 protein]; Sirolimus promotes the reaction [Ethanol results in increased expression of BCL2 protein] Sirolimus affects the expression of BCL2 protein Sirolimus inhibits the reaction [lactacystin results in decreased expression of BCL2 protein] [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2 mRNA Sirolimus results in decreased expression of BCL2 mRNA; Sirolimus results in decreased expression of BCL2 protein |
CTD |
PMID:11355896 PMID:15571967 PMID:18640276 PMID:19373661 PMID:19764996 PMID:19815708 PMID:21410490 PMID:29054700 PMID:30905858 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression decreases expression |
ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of BCL2L1 protein; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]; Sirolimus inhibits the reaction [rebamipide results in increased expression of BCL2L1 protein] Sirolimus results in increased expression of BCL2L1 mRNA; Sirolimus results in increased expression of BCL2L1 protein Sirolimus results in decreased expression of BCL2L1 mRNA; Sirolimus results in decreased expression of BCL2L1 protein [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2L1 mRNA; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein] |
CTD |
PMID:11355896 PMID:15767555 PMID:15782132 PMID:18097008 PMID:18789402 PMID:19922502 PMID:21681844 PMID:29054700 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions decreases expression increases expression |
ISO |
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; Sirolimus inhibits the reaction [rebamipide results in decreased expression of BCL2L11 protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of BCL2L11 mRNA] Sirolimus results in decreased expression of BCL2L11 protein Sirolimus results in increased expression of BCL2L11 protein |
CTD |
PMID:18097008 PMID:21092744 PMID:29054700 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B mRNA]; Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B protein] |
CTD |
PMID:17209049 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
ISO EXP |
[Sirolimus co-treated with TNF protein] results in increased expression of BECN1 protein; Sirolimus inhibits the reaction [Ethanol results in increased degradation of BECN1 protein]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of BECN1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [Caffeine results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [tris(1,3-dichloro-2-propyl)phosphate results in increased expression of BECN1 protein] [Sirolimus co-treated with cadmium acetate] results in increased expression of BECN1 mRNA; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of BECN1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [T-2 Toxin results in increased expression of BECN1 mRNA] Sirolimus results in increased expression of BECN1 protein Sirolimus results in increased expression of BECN1 mRNA; Sirolimus results in increased expression of BECN1 protein |
CTD |
PMID:20358864 PMID:21410490 PMID:26648565 PMID:26825372 PMID:27107786 PMID:28025121 PMID:28888487 PMID:29505745 PMID:29518472 PMID:29870746 PMID:30555576 PMID:30611790 PMID:30629952 PMID:30905858 PMID:31676321 PMID:32306690 PMID:32430275 PMID:32645460 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases expression decreases expression |
ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of BID protein Sirolimus results in increased expression of BID mRNA; Sirolimus results in increased expression of BID protein Sirolimus results in decreased expression of BID protein [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID protein |
CTD |
PMID:15767555 PMID:18097008 PMID:19922502 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions increases expression affects localization |
ISO EXP |
Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BIRC2 protein] Sirolimus results in increased expression of BIRC2 protein Sirolimus affects the localization of BIRC2 protein |
CTD |
PMID:15571967 PMID:21357504 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of BIRC5 mRNA; Sirolimus inhibits the reaction [N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide results in increased expression of and affects the localization of BIRC5 protein]; Sirolimus promotes the reaction [Tamoxifen results in decreased expression of BIRC5 protein] Sirolimus results in decreased expression of BIRC5 protein |
CTD |
PMID:19016759 PMID:19931998 PMID:21601561 PMID:24444656 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in increased expression of BNIP3 mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Btbd11 |
BTB domain containing 11 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of BTBD11 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 7:24,041,194...24,314,418
Ensembl chr 7:24,043,126...24,313,885
|
|
G |
Btc |
betacellulin |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [BTC protein results in increased expression of CCND1 protein] |
CTD |
PMID:19105244 |
|
NCBI chr14:18,231,854...18,270,621
Ensembl chr14:18,231,860...18,272,484
|
|
G |
Btk |
Bruton tyrosine kinase |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in increased expression of BTK mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr X:105,360,922...105,390,580
Ensembl chr X:105,360,922...105,390,580
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of BUB1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 3:120,373,604...120,404,910
Ensembl chr 3:120,373,604...120,404,910
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of BUB1B mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 3:110,367,949...110,420,471
Ensembl chr 3:110,367,939...110,420,458
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
EXP |
Sirolimus results in decreased expression of C1QA mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
|
|
G |
C1qc |
complement C1q C chain |
decreases expression |
EXP |
Sirolimus results in decreased expression of C1QC mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 5:155,255,013...155,258,631
Ensembl chr 5:155,255,005...155,258,392
|
|
G |
C3 |
complement C3 |
decreases expression |
EXP |
Sirolimus results in decreased expression of C3 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
|
|
G |
Cald1 |
caldesmon 1 |
multiple interactions increases expression |
ISO |
[Sirolimus co-treated with IGF1 protein] results in increased expression of CALD1 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of CALD1 protein Sirolimus results in increased expression of CALD1 protein |
CTD |
PMID:17908691 |
|
NCBI chr 4:62,103,948...62,291,375
Ensembl chr 4:62,220,736...62,291,489
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of CAMK2A protein] |
CTD |
PMID:21933187 |
|
NCBI chr18:56,193,978...56,295,869
Ensembl chr18:56,193,978...56,295,869
|
|
G |
Capn1 |
calpain 1 |
decreases activity |
EXP |
Sirolimus results in decreased activity of CAPN1 protein |
CTD |
PMID:21357504 |
|
NCBI chr 1:221,346,081...221,370,965
Ensembl chr 1:221,346,066...221,370,322
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO EXP |
Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein] Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of CASP1 protein modified form] |
CTD |
PMID:30205151 PMID:31586597 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp12 |
caspase 12 |
decreases cleavage multiple interactions |
ISO EXP |
Sirolimus results in decreased cleavage of CASP12 protein Sirolimus inhibits the reaction [cadmium acetate results in increased expression of CASP12 protein] |
CTD |
PMID:20511674 PMID:29870746 |
|
NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
[Boc-D-FMK co-treated with Sirolimus] results in increased cleavage of CASP2 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP2 protein] |
CTD |
PMID:15767555 |
|
NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression decreases activity increases activity increases cleavage |
ISO EXP |
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP3 protein; [Curcumin co-treated with Sirolimus] results in increased activity of CASP3 protein; [S 1 (combination) co-treated with Sirolimus] results in increased expression of CASP3 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein]; Fluorouracil promotes the reaction [Sirolimus results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [Ethanol results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Rotenone results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [TNF protein results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Doxorubicin results in increased activity of CASP3 protein]; Sirolimus promotes the reaction [Fluorouracil results in increased expression of CASP3 mRNA] Sirolimus results in increased expression of CASP3 protein modified form Sirolimus inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]]; Sirolimus promotes the reaction [Cadmium results in increased cleavage of CASP3 protein] Sirolimus results in decreased activity of CASP3 protein [Sirolimus co-treated with Resveratrol] results in increased cleavage of CASP3 protein; Sirolimus inhibits the reaction [decamethrin results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [T-2 Toxin results in increased expression of CASP3 protein modified form]; Sirolimus promotes the reaction [decamethrin results in increased cleavage of CASP3 protein]; Sirolimus results in decreased cleavage of and results in decreased activity of CASP3 protein Sirolimus results in increased expression of CASP3 mRNA; Sirolimus results in increased expression of CASP3 protein Sirolimus results in increased activity of CASP3 protein Sirolimus results in increased cleavage of CASP3 protein |
CTD |
PMID:14502240 PMID:15571967 PMID:15753396 PMID:15767555 PMID:15782132 PMID:15878982 PMID:16497721 PMID:18058806 PMID:18097008 PMID:19373661 PMID:19682553 PMID:19764996 PMID:20031680 PMID:20358864 PMID:21357504 PMID:21410490 PMID:21681844 PMID:24299490 PMID:24304514 PMID:26588882 PMID:26825372 PMID:28342888 PMID:29111403 PMID:30030080 PMID:30236763 PMID:30629952 PMID:31676321 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
multiple interactions decreases activity |
ISO EXP |
[Curcumin co-treated with Sirolimus] results in increased activity of CASP7 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP7 protein Sirolimus results in decreased activity of CASP7 protein |
CTD |
PMID:15753396 PMID:19373661 PMID:20031680 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP8 protein; [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP8 protein; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP8 protein] Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP8 protein]] Sirolimus results in increased cleavage of CASP8 protein |
CTD |
PMID:15767555 PMID:17121904 PMID:18058806 PMID:25307878 PMID:28342888 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions decreases activity |
ISO EXP |
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP9 protein; [Curcumin co-treated with Sirolimus] results in increased activity of CASP9 protein; [Sirolimus co-treated with Cisplatin] results in increased activity of CASP9 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP9 protein; [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP9 protein; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein] Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP9 protein]] Sirolimus inhibits the reaction [Staurosporine results in increased cleavage of CASP9 protein] Sirolimus results in decreased activity of CASP9 protein |
CTD |
PMID:15753396 PMID:15767555 PMID:16497721 PMID:17121904 PMID:18058806 PMID:18097008 PMID:19373661 PMID:20138251 PMID:28342888 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
increases expression |
ISO |
Sirolimus results in increased expression of CAT protein |
CTD |
PMID:30905858 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav3 |
caveolin 3 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of CAV3 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 4:144,382,945...144,398,919
Ensembl chr 4:144,382,945...144,398,917
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
EXP |
Sirolimus results in increased expression of CCN2 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of CCNA2 mRNA Sirolimus results in decreased expression of CCNA2 protein Sirolimus results in decreased expression of CCNA2; Sirolimus results in decreased expression of CCNA2 protein |
CTD |
PMID:7503980 PMID:8419408 PMID:19016759 PMID:19505958 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb2 |
cyclin B2 |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of CCNB2 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 8:76,847,972...76,861,165
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression increases expression increases degradation |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sirolimus results in increased expression of CCND1 protein]; [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with Sirolimus] results in decreased expression of CCND1; [3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CCND1 protein; [Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [SB 216763 results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Sirolimus co-treated with Letrozole] results in decreased expression of CCND1 protein; [Sirolimus co-treated with tanespimycin] results in decreased expression of CCND1 protein; [Sirolimus results in increased activity of GSK3B protein] which results in increased phosphorylation of and results in increased degradation of CCND1 protein Sirolimus inhibits the reaction [BTC protein results in increased expression of CCND1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of CCND1 protein] Sirolimus results in increased degradation of CCND1 protein |
CTD |
PMID:7532117 PMID:15753396 PMID:15767555 PMID:17121904 PMID:19105244 PMID:19505958 PMID:19661225 PMID:20054642 PMID:23006739 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions decreases expression |
ISO EXP |
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA] Sirolimus results in decreased expression of CCND2 protein Sirolimus inhibits the reaction [FSHB protein results in increased expression of CCND2 mRNA] |
CTD |
PMID:15070696 PMID:15778701 PMID:17510244 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Ccnd3 |
cyclin D3 |
multiple interactions decreases expression decreases stability |
ISO |
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA] Sirolimus results in decreased expression of CCND3 mRNA; Sirolimus results in decreased expression of CCND3 protein Sirolimus inhibits the reaction [KITL protein results in increased expression of CCND3 protein] Sirolimus results in decreased stability of CCND3 mRNA |
CTD |
PMID:10849422 PMID:12393642 PMID:15070696 PMID:15778701 PMID:15882288 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Ccne2 |
cyclin E2 |
multiple interactions |
ISO |
[Fulvestrant co-treated with Sirolimus] results in decreased expression of CCNE2 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA] |
CTD |
PMID:19016759 PMID:27542212 |
|
NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
|
|
G |
Ccng2 |
cyclin G2 |
multiple interactions increases expression |
ISO |
[cotylenin A co-treated with Sirolimus] results in increased expression of CCNG2 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CCNG2 mRNA] Sirolimus results in increased expression of CCNG2 mRNA |
CTD |
PMID:18754885 PMID:21245298 PMID:24356939 PMID:27542212 |
|
NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
|
|
G |
Ccni |
cyclin I |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in decreased expression of CCNI mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr14:16,341,510...16,364,326
Ensembl chr14:16,341,536...16,364,326
|
|
G |
Cd36 |
CD36 molecule |
affects expression multiple interactions |
ISO |
Sirolimus affects the expression of CD36 protein Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of CD36 mRNA] |
CTD |
PMID:17016853 PMID:19640849 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
CD38 gene mutant form promotes the reaction [Sirolimus results in increased expression of MAP1LC3B protein]; CD38 mutant form inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] |
CTD |
PMID:24238063 PMID:24445604 |
|
NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
|
|
G |
Cd68 |
Cd68 molecule |
decreases expression |
ISO EXP |
Sirolimus results in decreased expression of CD68 mRNA |
CTD |
PMID:17016853 PMID:21865292 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Cd80 |
Cd80 molecule |
decreases expression |
ISO |
Sirolimus results in decreased expression of CD80 protein |
CTD |
PMID:12531798 |
|
NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
|
|
G |
Cd84 |
CD84 molecule |
increases expression |
ISO |
Sirolimus results in increased expression of CD84 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:90,241,369...90,283,625
Ensembl chr13:90,244,681...90,277,865
|
|
G |
Cd86 |
CD86 molecule |
decreases expression |
ISO |
Sirolimus results in decreased expression of CD86 protein |
CTD |
PMID:12531798 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of CDC20 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
|
|
G |
Cdh1 |
cadherin 1 |
increases expression multiple interactions |
ISO EXP |
Sirolimus results in increased expression of CDH1 protein NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 mRNA]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]; Sirolimus promotes the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; Sirolimus promotes the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein] Sirolimus inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein] |
CTD |
PMID:28624451 PMID:28888487 PMID:30053495 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
EXP |
Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CDH2 mRNA]; Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CDH2 protein] |
CTD |
PMID:30053495 |
|
NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions decreases activity decreases expression |
ISO EXP |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CDK1 mRNA; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CDK1 protein; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of CDK1 protein; [fulvestrant co-treated with Sirolimus] results in decreased expression of CDK1 mRNA Sirolimus results in decreased activity of CDK1 protein Sirolimus results in decreased expression of CDK1 mRNA; Sirolimus results in decreased expression of CDK1 protein Sirolimus inhibits the reaction [IL2 protein results in increased expression of CDK1 mRNA] |
CTD |
PMID:7503980 PMID:7532117 PMID:8419408 PMID:11355896 PMID:15767555 PMID:19016759 PMID:19223503 PMID:19922502 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions decreases activity |
ISO EXP |
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of CDK2 protein [Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein] Sirolimus results in decreased activity of CDK2 protein |
CTD |
PMID:7532117 PMID:12393642 PMID:12417722 PMID:14979923 PMID:21528311 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Sirolimus results in decreased expression of CDK4 protein |
CTD |
PMID:22761470 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions decreases expression increases expression |
ISO EXP |
[(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of CDKN1A mRNA; [(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of CDKN1A protein; [S 1 (combination) co-treated with Sirolimus] results in increased expression of CDKN1A protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in increased expression of CDKN1A protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] results in increased expression of CDKN1A protein; Fluorouracil promotes the reaction [Sirolimus results in increased expression of CDKN1A mRNA]; Sirolimus inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]; Sirolimus promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A mRNA]; Sirolimus promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A protein]; Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]; Sirolimus promotes the reaction [Fluorouracil results in increased expression of CDKN1A mRNA] Sirolimus results in decreased expression of CDKN1A protein Sirolimus results in increased expression of CDKN1A mRNA; Sirolimus results in increased expression of CDKN1A protein Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1A protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] |
CTD |
PMID:12417722 PMID:14979923 PMID:17700525 PMID:19105244 PMID:19764996 PMID:21528311 PMID:22561310 PMID:25307878 PMID:30555576 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions decreases expression increases expression decreases degradation |
ISO EXP |
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; [Decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of CDKN1B mRNA; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of CDKN1B mRNA] Sirolimus results in decreased expression of CDKN1B protein Sirolimus results in increased expression of CDKN1B protein Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1B protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein] Sirolimus results in decreased degradation of CDKN1B protein |
CTD |
PMID:12417722 PMID:12565877 PMID:14979923 PMID:15070696 PMID:16455087 PMID:18622747 PMID:19105244 PMID:21092744 PMID:22561310 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdx2 |
caudal type homeo box 2 |
increases expression |
ISO |
Sirolimus results in increased expression of CDX2 mRNA |
CTD |
PMID:21681844 |
|
NCBI chr12:9,464,026...9,470,565
Ensembl chr12:9,464,026...9,470,565
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression |
ISO |
Sirolimus results in decreased expression of CEBPA mRNA |
CTD |
PMID:15358118 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Cenpx |
centromere protein X |
increases expression |
ISO |
Sirolimus results in increased expression of CENPX mRNA |
CTD |
PMID:11355896 |
|
NCBI chr10:109,890,904...109,893,804
|
|
G |
Cfd |
complement factor D |
decreases expression |
ISO |
Sirolimus results in decreased expression of CFD mRNA |
CTD |
PMID:15358118 |
|
NCBI chr 7:12,634,216...12,635,939
Ensembl chr 7:12,634,216...12,635,943
|
|
G |
Chrnb3 |
cholinergic receptor nicotinic beta 3 subunit |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of CHRNB3 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr16:68,876,442...68,913,628
Ensembl chr16:68,875,709...68,913,628
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of CIDEC mRNA] |
CTD |
PMID:31499194 |
|
NCBI chr 4:145,377,482...145,390,497
Ensembl chr 4:145,377,431...145,390,497
|
|
G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
decreases expression |
ISO |
Sirolimus results in decreased expression of CKS1B mRNA |
CTD |
PMID:11355896 |
|
NCBI chr 2:188,740,564...188,745,144
Ensembl chr 2:188,740,573...188,745,144
|
|
G |
Cldn7 |
claudin 7 |
increases expression |
EXP |
Sirolimus results in increased expression of CLDN7 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr10:56,576,326...56,578,632
Ensembl chr10:56,576,428...56,578,626
|
|
G |
Clec4a3 |
C-type lectin domain family 4, member A3 |
decreases expression |
EXP |
Sirolimus results in decreased expression of CLEC4A mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 4:155,913,366...155,923,079
Ensembl chr 4:155,913,366...155,923,079
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
EXP |
Sirolimus results in decreased expression of COL1A1 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions |
ISO EXP |
Sirolimus inhibits the reaction [Acetaldehyde results in increased expression of COL1A2 mRNA] Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A2 mRNA] |
CTD |
PMID:10535884 PMID:11343241 |
|
NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
|
|
G |
Cp |
ceruloplasmin |
increases expression |
EXP |
Sirolimus results in increased expression of CP mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]] |
CTD |
PMID:25045214 |
|
NCBI chr 7:130,395,211...130,404,731
Ensembl chr 7:130,395,194...130,405,347
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]] |
CTD |
PMID:25045214 |
|
NCBI chr 5:127,505,646...127,523,016
Ensembl chr 5:127,505,614...127,523,089
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein]] |
CTD |
PMID:22363816 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crebrf |
CREB3 regulatory factor |
multiple interactions |
ISO |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of CREBRF mRNA |
CTD |
PMID:25307878 |
|
NCBI chr10:16,693,846...16,753,162
Ensembl chr10:16,694,792...16,752,205
|
|
G |
Crtc2 |
CREB regulated transcription coactivator 2 |
decreases activity |
ISO |
Sirolimus results in decreased activity of CRTC2 protein |
CTD |
PMID:23440206 |
|
NCBI chr 2:189,615,928...189,625,646
Ensembl chr 2:189,615,948...189,626,051
|
|
G |
Cse1l |
chromosome segregation 1 like |
decreases expression |
ISO |
Sirolimus results in decreased expression of CSE1L mRNA |
CTD |
PMID:11355896 |
|
NCBI chr 3:163,664,074...163,702,074
Ensembl chr 3:163,664,136...163,702,060
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:14502240 |
|
NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of CSF2 protein]] |
CTD |
PMID:1376361 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:30053495 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctsk |
cathepsin K |
multiple interactions decreases expression |
ISO |
PDCD4 mutant form inhibits the reaction [Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased activity of CTSK protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA] Sirolimus results in decreased expression of CTSK mRNA |
CTD |
PMID:26369790 |
|
NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
decreases expression |
EXP |
Sirolimus results in decreased expression of CXCL10 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
decreases expression |
EXP |
Sirolimus results in decreased expression of CXCL13 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr14:15,253,146...15,258,221
Ensembl chr14:15,253,125...15,258,207
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of CYBA protein] |
CTD |
PMID:21195169 |
|
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of CYBB protein] |
CTD |
PMID:21195169 |
|
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO |
[Cyclosporine co-treated with Sirolimus] results in decreased activity of CYP27A1 protein Sirolimus results in decreased activity of CYP27A1 protein |
CTD |
PMID:17516993 |
|
NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
Sirolimus results in increased expression of CYP2B6 mRNA |
CTD |
PMID:25929522 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases expression increases expression |
ISO |
Sirolimus results in decreased expression of CYP2C9 protein Sirolimus results in increased expression of CYP2C9 mRNA |
CTD |
PMID:25929522 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
affects metabolic processing |
ISO |
CYP3A4 protein affects the metabolism of Sirolimus; CYP3A4 protein polymorphism affects the metabolism of Sirolimus |
CTD |
PMID:15707415 PMID:15964407 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO EXP |
Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [Hydrogen Peroxide results in increased expression of DDIT3 protein] [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of DDIT3 mRNA; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of DDIT3 protein; Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 mRNA]; Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 protein] Sirolimus inhibits the reaction [cadmium acetate results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of DDIT3 protein] |
CTD |
PMID:11145585 PMID:19420259 PMID:21321189 PMID:22215663 PMID:25307878 PMID:29870746 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
increases expression decreases expression |
EXP |
Sirolimus results in increased expression of DDIT4L mRNA Sirolimus results in decreased expression of DDIT4L mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 2:242,882,219...242,885,088
Ensembl chr 2:242,882,306...242,885,131
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of DEPTOR mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 7:94,795,161...95,000,750
Ensembl chr 7:94,795,214...94,995,809
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions |
ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] affects the localization of DIABLO protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] affects the localization of DIABLO protein] |
CTD |
PMID:15767555 |
|
NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
|
|
G |
Dnajc6 |
DnaJ heat shock protein family (Hsp40) member C6 |
decreases expression |
EXP |
Sirolimus results in decreased expression of DNAJC6 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 5:120,330,372...120,492,515
Ensembl chr 5:120,340,646...120,492,487
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of DNMT1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
decreases expression |
ISO |
Sirolimus results in decreased expression of DPYD mRNA |
CTD |
PMID:19764996 |
|
NCBI chr 2:221,823,692...222,694,627
Ensembl chr 2:221,823,687...222,694,627
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
increases expression |
ISO |
Sirolimus results in increased expression of DUSP10 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455
|
|
G |
Dusp15 |
dual specificity phosphatase 15 |
decreases expression |
EXP |
Sirolimus results in decreased expression of DUSP15 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 3:148,417,990...148,428,494
Ensembl chr 3:148,417,993...148,428,494
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 mRNA; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein |
CTD |
PMID:12417722 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
E2f4 |
E2F transcription factor 4 |
multiple interactions |
ISO |
[TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein] |
CTD |
PMID:12417722 |
|
NCBI chr19:37,252,828...37,260,239
Ensembl chr19:37,252,843...37,260,239
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [EDN1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:12411397 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
increases phosphorylation |
ISO |
Sirolimus results in increased phosphorylation of EEF2 protein |
CTD |
PMID:25940091 |
|
NCBI chr 7:11,401,501...11,406,771
Ensembl chr 7:11,401,501...11,406,771
|
|
G |
Egf |
epidermal growth factor |
multiple interactions decreases activity |
ISO |
Sirolimus inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein] Sirolimus analog results in decreased activity of EGF protein |
CTD |
PMID:12406821 PMID:21187475 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK3 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of EGFR protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein]; Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein |
CTD |
PMID:19151764 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [cadmium acetate results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:29870746 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Eif4b |
eukaryotic translation initiation factor 4B |
multiple interactions decreases phosphorylation |
ISO EXP |
[resveratrol co-treated with Sirolimus] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; [Sirolimus co-treated with resveratrol] results in decreased phosphorylation of EIF4B protein; Sirolimus inhibits the reaction [sodium arsenite results in increased phosphorylation of EIF4B protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein] Sirolimus results in decreased phosphorylation of EIF4B protein [resveratrol co-treated with Sirolimus] results in decreased phosphorylation of EIF4B protein |
CTD |
PMID:21268130 PMID:24304514 PMID:24375594 |
|
NCBI chr 7:143,679,656...143,701,452
Ensembl chr 7:143,679,617...143,701,452
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions increases phosphorylation decreases activity |
ISO EXP |
EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein] Sirolimus results in increased phosphorylation of EIF4E protein Sirolimus inhibits the reaction [Phenylephrine results in increased phosphorylation of EIF4E protein] Sirolimus results in decreased activity of EIF4E protein |
CTD |
PMID:15757502 PMID:19560264 PMID:26282490 |
|
NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions affects phosphorylation decreases phosphorylation |
ISO EXP |
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus co-treated with Cisplatin] results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of EIF4EBP1 protein; KIT protein mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus affects the reaction [Testosterone results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [Acetaldehyde results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [Cisplatin results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [sodium arsenite results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein; sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein] Sirolimus affects the phosphorylation of EIF4EBP1 protein Sirolimus inhibits the reaction [Cadmium results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Phenylephrine results in increased phosphorylation of EIF4EBP1 protein] Sirolimus inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus results in decreased phosphorylation of and results in increased activity of EIF4EBP1 protein; Tacrolimus inhibits the reaction [Sirolimus results in decreased phosphorylation of and results in increased activity of EIF4EBP1 protein] |
CTD |
PMID:8599949 PMID:8971030 PMID:11909977 PMID:12411397 PMID:12939469 PMID:14502240 PMID:14673156 PMID:15782132 PMID:15806154 PMID:16255777 PMID:16597595 PMID:16962100 PMID:18021293 PMID:18058806 PMID:18622747 PMID:19478560 PMID:19560264 PMID:19853261 PMID:20169165 PMID:20863555 PMID:21036700 PMID:21321189 PMID:21898527 PMID:21933187 PMID:22869613 PMID:23363784 PMID:24299490 PMID:24375594 PMID:25940091 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4 gamma, 1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to PABPC1 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPL32 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS20 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS6 mRNA] |
CTD |
PMID:25940091 |
|
NCBI chr11:83,907,659...83,927,683
Ensembl chr11:83,908,109...83,926,524
|
|
G |
Eif4g2 |
eukaryotic translation initiation factor 4, gamma 2 |
increases expression |
ISO |
Sirolimus results in increased expression of EIF4G2 protein |
CTD |
PMID:18491231 |
|
NCBI chr 1:175,883,362...175,895,510
Ensembl chr 1:175,883,363...175,895,510
|
|
G |
Eno2 |
enolase 2 |
multiple interactions increases expression |
EXP |
3-methyladenine inhibits the reaction [Sirolimus results in increased expression of ENO2 protein]; Chloroquine inhibits the reaction [Sirolimus results in increased expression of ENO2 protein] |
CTD |
PMID:26676567 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein] Sirolimus inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:24898257 PMID:32283200 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of ERO1A mRNA] |
CTD |
PMID:19420259 |
|
NCBI chr15:19,619,947...19,655,381
Ensembl chr15:19,619,973...19,655,381
|
|
G |
Espl1 |
extra spindle pole bodies like 1, separase |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of ESPL1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 7:143,896,890...143,923,868
Ensembl chr 7:143,897,014...143,923,868
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression increases phosphorylation |
ISO |
Sirolimus results in increased expression of ESR1 protein Sirolimus results in increased phosphorylation of ESR1 protein |
CTD |
PMID:19016759 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Evi2a |
ecotropic viral integration site 2A |
increases expression |
ISO |
Sirolimus results in increased expression of EVI2A mRNA |
CTD |
PMID:24356939 |
|
NCBI chr10:66,870,048...66,873,948
Ensembl chr10:66,870,067...66,873,948
|
|
G |
Ewsr1 |
EWS RNA-binding protein 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of EWSR1 protein mutant form |
CTD |
PMID:15782132 |
|
NCBI chr14:85,322,105...85,350,826
Ensembl chr14:85,322,296...85,350,948
|
|
G |
F2 |
coagulation factor II |
decreases expression |
EXP |
Sirolimus results in decreased expression of F2 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases activity |
ISO |
Sirolimus promotes the reaction [TNF protein results in increased expression of F3 protein] Sirolimus results in increased activity of F3 protein |
CTD |
PMID:19567381 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
Sirolimus results in decreased expression of FAS mRNA |
CTD |
PMID:15358118 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
decreases secretion |
ISO |
Sirolimus results in decreased secretion of FASLG protein |
CTD |
PMID:11692113 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Faxdc2 |
fatty acid hydroxylase domain containing 2 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of FAXDC2 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr10:43,500,825...43,526,376
Ensembl chr10:43,502,931...43,512,287
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
EXP |
Sirolimus results in increased expression of FBLN1 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 7:126,096,793...126,176,468
Ensembl chr 7:126,096,793...126,176,468
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions increases expression |
ISO |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of FBXO32 mRNA; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FBXO32 mRNA] Sirolimus results in increased expression of FBXO32 mRNA |
CTD |
PMID:21245298 PMID:24356939 PMID:25307878 |
|
NCBI chr 7:98,065,664...98,098,071
Ensembl chr 7:98,063,735...98,098,268
|
|
G |
Fbxo5 |
F-box protein 5 |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of FBXO5 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 1:42,461,277...42,467,646
Ensembl chr 1:42,461,291...42,467,586
|
|
G |
Fcgr1a |
Fc fragment of IgG receptor Ia |
multiple interactions decreases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arsenic trioxide inhibits the reaction [Sirolimus results in decreased expression of FCGR1A protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Sirolimus results in decreased expression of FCGR1A protein]; arsenic trioxide inhibits the reaction [Sirolimus results in decreased expression of FCGR1A protein] |
CTD |
PMID:25758096 |
|
NCBI chr 2:198,430,536...198,439,453
Ensembl chr 2:198,430,530...198,458,041
|
|
G |
Fgb |
fibrinogen beta chain |
decreases expression increases expression |
EXP |
Sirolimus results in decreased expression of FGB mRNA Sirolimus results in increased expression of FGB mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 2:182,028,044...182,035,026
Ensembl chr 2:182,027,115...182,038,178
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
EXP |
[Sirolimus co-treated with Hydrogen Peroxide] results in increased expression of FGF1 mRNA; Sirolimus inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] |
CTD |
PMID:15121739 PMID:31332898 |
|
NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of FGF21 mRNA] |
CTD |
PMID:31499194 |
|
NCBI chr 1:101,595,579...101,596,822
Ensembl chr 1:101,595,579...101,596,822
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of FGF7 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
affects binding multiple interactions |
ISO EXP |
Sirolimus binds to FKBP1A protein immunomycin inhibits the reaction [Sirolimus binds to FKBP1A protein] [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG protein; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R protein; [Sirolimus binds to FKBP1A protein] which results in increased expression of ACTB mRNA; immunomycin inhibits the reaction [Sirolimus binds to FKBP1A protein] [Sirolimus binds to FKBP1A protein] which results in increased activity of TGFB1 protein; [Tacrolimus binds to FKBP1A protein] inhibits the reaction [Sirolimus binds to FKBP1A protein] |
CTD |
PMID:7503980 PMID:7532117 PMID:10361256 PMID:12417722 PMID:12531798 PMID:17438408 |
|
NCBI chr 3:147,042,944...147,062,725
Ensembl chr 3:147,042,944...147,062,724
|
|
G |
Flt3lg |
Fms related receptor tyrosine kinase 3 ligand |
decreases activity |
ISO |
Sirolimus results in decreased activity of FLT3LG protein |
CTD |
PMID:12531798 |
|
NCBI chr 1:101,126,006...101,131,413
Ensembl chr 1:101,124,479...101,131,413
|
|
G |
Folr1 |
folate receptor alpha |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of FOLR1 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 1:166,934,457...166,945,864
Ensembl chr 1:166,934,460...166,943,592
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of FOXM1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 4:161,685,236...161,697,633
Ensembl chr 4:161,685,258...161,696,305
|
|
G |
Foxo1 |
forkhead box O1 |
increases phosphorylation |
ISO |
Sirolimus results in increased phosphorylation of FOXO1 protein |
CTD |
PMID:16227402 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions increases phosphorylation |
ISO |
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of and results in increased localization of and results in increased activity of FOXO3 protein]; Sirolimus results in decreased degradation of and results in increased phosphorylation of FOXO3 protein |
CTD |
PMID:21092744 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Foxp1 |
forkhead box P1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of FOXP1 protein |
CTD |
PMID:25663935 |
|
NCBI chr 4:131,362,178...131,963,466
Ensembl chr 4:131,366,744...131,694,755
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions increases expression |
ISO |
[TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 protein Sirolimus results in increased expression of FOXP3 mRNA |
CTD |
PMID:20844194 |
|
NCBI chr X:15,753,175...15,768,648
Ensembl chr X:15,753,175...15,768,522
|
|
G |
Frat1 |
FRAT regulator of WNT signaling pathway 1 |
increases expression |
ISO |
Sirolimus results in increased expression of FRAT1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:261,071,965...261,075,244
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [FSHB protein results in increased expression of CCND2 mRNA] |
CTD |
PMID:17510244 |
|
NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of FTL mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Gabarap |
GABA type A receptor-associated protein |
increases expression |
ISO |
Sirolimus results in increased expression of GABARAP mRNA |
CTD |
PMID:21681844 |
|
NCBI chr10:56,601,288...56,604,223
Ensembl chr10:56,601,288...56,604,221
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
multiple interactions |
ISO |
Sirolimus affects the localization of and results in increased lipidation of GABARAPL1 protein |
CTD |
PMID:15888080 |
|
NCBI chr 4:163,293,724...163,302,866
Ensembl chr 4:163,293,724...163,302,858
|
|
G |
Gcm2 |
glial cells missing transcription factor 2 |
multiple interactions |
ISO |
Sirolimus promotes the reaction [TP73 protein affects the activity of GCM2 protein] |
CTD |
PMID:21245298 |
|
NCBI chr17:21,490,402...21,499,516
Ensembl chr17:21,490,402...21,499,516
|
|
G |
Gem |
GTP binding protein overexpressed in skeletal muscle |
multiple interactions |
ISO |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of GEM mRNA |
CTD |
PMID:25307878 |
|
NCBI chr 5:25,339,479...25,353,661
Ensembl chr 5:25,349,928...25,353,661
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
EXP |
Sirolimus promotes the reaction [Cyclosporine affects the expression of GGT1 protein] |
CTD |
PMID:11589784 |
|
NCBI chr20:14,019,723...14,045,781
Ensembl chr20:14,019,723...14,025,068
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions decreases expression |
EXP |
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]; Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]] Sirolimus results in decreased expression of GLB1 protein |
CTD |
PMID:22561310 |
|
NCBI chr 8:122,439,328...122,511,939
Ensembl chr 8:122,439,328...122,511,939
|
|
G |
Gper1 |
G protein-coupled estrogen receptor 1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [puerarin results in increased expression of GPER1 protein] |
CTD |
PMID:27796870 |
|
NCBI chr12:17,309,122...17,315,267
Ensembl chr12:17,309,834...17,311,112
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
EXP |
Sirolimus results in increased expression of GPNMB mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683
|
|
G |
Gpr18 |
G protein-coupled receptor 18 |
increases expression |
ISO |
Sirolimus results in increased expression of GPR18 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr15:108,323,157...108,326,907
Ensembl chr15:108,323,179...108,326,907
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
Sirolimus promotes the reaction [Cyclosporine affects the expression of GPT protein] Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased activity of GPT protein]] |
CTD |
PMID:11589784 PMID:31499194 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases activity |
ISO |
[3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [SB 216763 results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in increased phosphorylation of GSK3B protein; [Sirolimus results in increased activity of GSK3B protein] which results in increased phosphorylation of and results in increased degradation of CCND1 protein Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:15753396 PMID:17908691 PMID:18495876 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
increases response to substance |
ISO |
GSTT1 gene mutant form results in increased susceptibility to Sirolimus |
CTD |
PMID:12916871 |
|
NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
|
|
G |
Gtpbp4 |
GTP binding protein 4 |
decreases expression |
EXP |
Sirolimus results in decreased expression of GTPBP4 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr17:63,111,086...63,145,618
Ensembl chr17:63,110,254...63,145,577
|
|
G |
Guca2a |
guanylate cyclase activator 2A |
increases expression |
EXP |
Sirolimus results in increased expression of GUCA2A mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 5:138,685,634...138,687,476
Ensembl chr 5:138,685,624...138,687,816
|
|
G |
Gzmb |
granzyme B |
decreases expression |
ISO |
Sirolimus results in decreased expression of GZMB protein |
CTD |
PMID:16477233 |
|
NCBI chr15:35,413,862...35,417,293
Ensembl chr15:35,413,793...35,417,316
|
|
G |
H2ax |
H2A.X variant histone |
decreases expression |
ISO |
Sirolimus results in decreased expression of H2AX protein |
CTD |
PMID:23363784 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
EXP |
Sirolimus results in increased expression of HAVCR1 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
multiple interactions |
ISO |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of HBP1 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA] |
CTD |
PMID:25307878 PMID:27542212 |
|
NCBI chr 6:51,231,479...51,257,699
Ensembl chr 6:51,231,480...51,257,625
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of HES1 protein Sirolimus results in decreased expression of HES1 mRNA; Sirolimus results in decreased expression of HES1 protein |
CTD |
PMID:20038814 |
|
NCBI chr11:74,312,837...74,315,249
Ensembl chr11:74,312,806...74,315,248
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
ISO EXP |
[Curcumin analog co-treated with Sirolimus] inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [4-hydroxyestradiol results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A mRNA]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [sulprostone results in increased expression of HIF1A protein] Sirolimus results in decreased expression of HIF1A mRNA Sirolimus results in decreased expression of HIF1A protein |
CTD |
PMID:15050414 PMID:15297429 PMID:15634505 PMID:16682453 PMID:17968710 PMID:19335982 PMID:19640849 PMID:20335389 PMID:20554536 PMID:21984483 PMID:28574600 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
Sirolimus results in increased expression of HMGCR mRNA |
CTD |
PMID:17516993 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Sirolimus results in increased expression of HMOX1 Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of HMOX1 protein] |
CTD |
PMID:17003813 PMID:19420259 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnrnpd |
heterogeneous nuclear ribonucleoprotein D |
decreases expression increases expression |
ISO EXP |
Sirolimus results in decreased expression of HNRNPD protein Sirolimus results in increased expression of HNRNPD protein |
CTD |
PMID:17603996 |
|
NCBI chr14:11,256,163...11,274,684
Ensembl chr14:11,256,268...11,274,578
|
|
G |
Hoxa9 |
homeobox A9 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein affects the activity of HOXA9 protein] |
CTD |
PMID:21245298 |
|
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein; [Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein] Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR146A mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR193A-1 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR21-1 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR21-2 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:24898257 PMID:30619488 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
decreases expression |
ISO |
Sirolimus results in decreased expression of HSPA1B mRNA |
CTD |
PMID:24356939 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression multiple interactions |
ISO EXP |
Sirolimus results in decreased expression of HSPA5 mRNA Sirolimus inhibits the reaction [cadmium acetate results in increased expression of HSPA5 protein] [Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein] |
CTD |
PMID:24356939 PMID:24898257 PMID:29870746 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspb8 |
heat shock protein family B (small) member 8 |
decreases expression |
ISO |
Sirolimus results in decreased expression of HSPB8 protein |
CTD |
PMID:21233418 |
|
NCBI chr12:45,905,371...45,920,014
Ensembl chr12:45,905,371...45,920,013
|
|
G |
Ibsp |
integrin-binding sialoprotein |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased expression of IBSP protein] |
CTD |
PMID:31051157 |
|
NCBI chr14:6,801,200...6,813,987
Ensembl chr14:6,801,204...6,813,945
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of ICAM1 protein |
CTD |
PMID:12531798 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
increases expression |
ISO |
Sirolimus results in increased expression of ID1 mRNA |
CTD |
PMID:23824090 PMID:24356939 |
|
NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases secretion |
ISO |
Sirolimus inhibits the reaction [IFNG protein results in decreased phosphorylation of STAT3 protein] Sirolimus inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein] Sirolimus results in decreased secretion of IFNG protein |
CTD |
PMID:11692113 PMID:16427044 PMID:21600178 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions increases response to substance |
ISO EXP |
[Dexamethasone co-treated with Sirolimus] inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] results in decreased activity of IGF1 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of ACTA2 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of CALD1 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of MYH11 protein; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of IGFBP3 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of VEGFA protein] Sirolimus inhibits the reaction [[IGF1 protein co-treated with U 0126] promotes the reaction [Isoflurane results in decreased phosphorylation of MAPK1 protein]]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of CCND1 protein] Sirolimus results in increased susceptibility to IGF1 protein Sirolimus inhibits the reaction [IL2 protein results in increased expression of IGF1 mRNA] |
CTD |
PMID:11355896 PMID:15070696 PMID:15297429 PMID:16227402 PMID:16682453 PMID:17908691 PMID:19105244 PMID:25597859 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
affects activity multiple interactions |
ISO |
Sirolimus affects the activity of IGF1R protein Sirolimus promotes the reaction [IGF1R protein binds to and results in increased phosphorylation of IRS1 protein] |
CTD |
PMID:16227402 |
|
NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
EXP |
Sirolimus results in increased expression of IGFBP1 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of IGFBP3 protein] |
CTD |
PMID:16682453 |
|
NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases expression |
EXP |
Sirolimus results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 9:80,154,230...80,166,813
Ensembl chr 9:80,150,211...80,167,033
|
|
G |
Il10 |
interleukin 10 |
multiple interactions decreases expression |
ISO |
Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]; Sirolimus inhibits the reaction [lipoteichoic acid results in increased expression of IL10 protein]; Sirolimus inhibits the reaction [Peptidoglycan results in increased expression of IL10 protein] Sirolimus results in decreased expression of IL10 mRNA Sirolimus results in decreased expression of IL10 protein [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]] |
CTD |
PMID:11169223 PMID:15588918 PMID:31499194 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:12531798 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:12531798 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il17rb |
interleukin 17 receptor B |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of IL17RB mRNA |
CTD |
PMID:19016759 |
|
NCBI chr16:6,064,287...6,077,978
Ensembl chr16:6,064,288...6,077,978
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL18 protein] |
CTD |
PMID:30205151 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression affects expression |
ISO EXP |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]] Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL1B protein] Sirolimus results in increased expression of IL1B mRNA Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of IL1B protein modified form]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of IL1B protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]] Sirolimus results in increased expression of IL1B protein Sirolimus affects the expression of IL1B mRNA |
CTD |
PMID:22363816 PMID:23211629 PMID:24971338 PMID:25045214 PMID:29594315 PMID:30205151 PMID:31499194 PMID:31586597 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions affects expression decreases response to substance |
ISO EXP |
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein]; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RBL2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein] Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]] Sirolimus affects the expression of IL2 protein [Sirolimus co-treated with IL2 protein] results in decreased expression of BCL2A1A mRNA; [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2 mRNA; [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2L1 mRNA; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; Sirolimus inhibits the reaction [IL2 protein results in decreased expression of CCNI mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of ASNS mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BAD mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BNIP3 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BTK mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CDK1 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of IGF1 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM2 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM7 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of PCNA mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]] Sirolimus results in decreased susceptibility to IL2 protein |
CTD |
PMID:1614535 PMID:10373522 PMID:11355896 PMID:15588918 PMID:15778701 PMID:24971338 PMID:25045214 PMID:29594315 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL2RA protein] |
CTD |
PMID:8586487 |
|
NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
|
|
G |
Il2rg |
interleukin 2 receptor subunit gamma |
multiple interactions |
ISO |
[Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG protein |
CTD |
PMID:12531798 |
|
NCBI chr X:71,165,378...71,169,078
Ensembl chr X:71,162,585...71,169,865
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL3 protein]] |
CTD |
PMID:1376361 |
|
NCBI chr10:39,620,535...39,622,973
Ensembl chr10:39,620,563...39,622,973
|
|
G |
Il4 |
interleukin 4 |
multiple interactions decreases expression |
ISO |
[Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]] Sirolimus analog results in decreased expression of IL4 protein; Sirolimus results in decreased expression of IL4 protein |
CTD |
PMID:12406821 PMID:12531798 PMID:15588918 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il4r |
interleukin 4 receptor |
multiple interactions |
ISO |
[Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R protein |
CTD |
PMID:12531798 |
|
NCBI chr 1:196,942,343...196,967,221
Ensembl chr 1:196,942,364...196,967,220
|
|
G |
Il5 |
interleukin 5 |
decreases expression |
ISO |
Sirolimus analog results in decreased expression of IL5 protein |
CTD |
PMID:12406821 |
|
NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression decreases expression |
ISO |
[Dexamethasone co-treated with Sirolimus] inhibits the reaction [IL6 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] results in decreased activity of IL6 protein; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 protein Sirolimus results in increased expression of IL6 Sirolimus results in decreased expression of IL6 mRNA |
CTD |
PMID:15070696 PMID:16314788 PMID:20844194 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ing4 |
inhibitor of growth family, member 4 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of ING4 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 4:157,554,729...157,563,353
Ensembl chr 4:157,554,794...157,563,352
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein results in increased expression of IRS1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK3 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:20936651 PMID:28790194 PMID:28984034 PMID:32283200 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
ISO |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of INSIG1 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515
|
|
G |
Irs1 |
insulin receptor substrate 1 |
affects phosphorylation decreases phosphorylation decreases degradation multiple interactions |
ISO |
Sirolimus affects the phosphorylation of IRS1 protein Sirolimus results in decreased phosphorylation of IRS1 protein Sirolimus results in decreased degradation of IRS1 protein [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased activity of IRS1 protein; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein results in increased expression of IRS1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of IRS1 protein]; Sirolimus promotes the reaction [IGF1R protein binds to and results in increased phosphorylation of IRS1 protein]; Sirolimus promotes the reaction [IRS1 protein binds to PIK3R1 protein] |
CTD |
PMID:16227402 PMID:17908691 PMID:20936651 PMID:28984034 |
|
NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Sirolimus co-treated with arsenic trioxide] results in increased expression of ITGAM protein]; [Sirolimus co-treated with arsenic trioxide] results in increased expression of ITGAM protein; Sirolimus promotes the reaction [Tretinoin results in increased localization of and results in increased expression of ITGAM protein] Sirolimus results in increased expression of ITGAM protein |
CTD |
PMID:20574048 PMID:25758096 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Itgav |
integrin subunit alpha V |
decreases expression |
ISO |
Sirolimus results in decreased expression of ITGAV mRNA; Sirolimus results in decreased expression of ITGAV protein |
CTD |
PMID:19922502 |
|
NCBI chr 3:71,113,269...71,205,958
Ensembl chr 3:71,114,100...71,202,411
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of JAG1 protein |
CTD |
PMID:20038814 |
|
NCBI chr 3:130,079,361...130,114,781
Ensembl chr 3:130,079,361...130,114,770
|
|
G |
Jmy |
junction mediating and regulatory protein, p53 cofactor |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of JMY mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 2:23,026,506...23,097,702
Ensembl chr 2:23,042,189...23,097,610
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of JUN protein] |
CTD |
PMID:26369790 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kifap3 |
kinesin-associated protein 3 |
increases expression |
EXP |
Sirolimus results in increased expression of KIFAP3 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr13:82,072,497...82,217,256
Ensembl chr13:82,072,497...82,217,252
|
|
G |
Kifc1 |
kinesin family member C1 |
decreases expression |
EXP |
Sirolimus results in decreased expression of KIFC1 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr20:5,509,059...5,526,175
Ensembl chr20:5,509,059...5,526,175
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
multiple interactions |
ISO |
KIT protein mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:16597595 |
|
NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [KITL protein results in increased expression of CCND3 protein]; Sirolimus inhibits the reaction [KITL protein results in increased phosphorylation of RB1 protein] |
CTD |
PMID:10849422 |
|
NCBI chr 7:42,269,784...42,351,054
Ensembl chr 7:42,269,784...42,351,054
|
|
G |
Klf2 |
Kruppel-like factor 2 |
increases expression |
ISO |
Sirolimus results in increased expression of KLF2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr16:19,223,087...19,225,037
Ensembl chr16:19,223,087...19,225,037
|
|
G |
Klf5 |
Kruppel-like factor 5 |
increases expression |
EXP |
Sirolimus results in increased expression of KLF5 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
|
|
G |
Klf6 |
Kruppel-like factor 6 |
decreases phosphorylation |
ISO |
Sirolimus results in decreased phosphorylation of KLF6 protein |
CTD |
PMID:16611854 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Klhl24 |
kelch-like family member 24 |
increases expression multiple interactions |
ISO |
Sirolimus results in increased expression of KLHL24 mRNA [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of KLHL24 mRNA |
CTD |
PMID:24356939 PMID:25307878 |
|
NCBI chr11:84,613,101...84,643,674
Ensembl chr11:84,615,760...84,633,504
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
decreases expression |
EXP |
Sirolimus results in decreased expression of KLK1C10 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:99,890,294...99,894,353
Ensembl chr 1:99,890,294...99,894,353
|
|
G |
Klk1c9 |
kallikrein 1-related peptidase C9 |
decreases expression |
EXP |
Sirolimus results in decreased expression of KLK1C9 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:100,086,520...100,090,406
Ensembl chr 1:100,059,967...100,203,329
|
|
G |
L1cam |
L1 cell adhesion molecule |
affects response to substance |
ISO |
L1CAM affects the susceptibility to Sirolimus |
CTD |
PMID:21097529 |
|
NCBI chr X:156,901,244...156,928,064
Ensembl chr X:156,909,913...156,928,057
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
EXP |
Sirolimus results in increased expression of LAMC2 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr13:70,566,643...70,632,126
Ensembl chr13:70,566,643...70,626,252
|
|
G |
Larp1 |
La ribonucleoprotein 1, translational regulator |
multiple interactions increases response to substance |
ISO |
LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPL32 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS20 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS6 protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus promotes the reaction [LARP1 protein binds to PABPC1 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPL32 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS20 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS6 mRNA] LARP1 protein results in increased susceptibility to Sirolimus |
CTD |
PMID:25940091 |
|
NCBI chr10:43,435,738...43,501,186
Ensembl chr10:43,446,526...43,498,066
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
EXP |
Sirolimus results in increased expression of LCN2 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Lipe |
lipase E, hormone sensitive type |
multiple interactions |
ISO |
Sirolimus promotes the reaction [Isoproterenol results in increased phosphorylation of LIPE protein] |
CTD |
PMID:21042876 |
|
NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
|
|
G |
LOC685081 |
similar to solute carrier family 22 (organic cation transporter), member 13 |
decreases expression |
EXP |
Sirolimus results in decreased expression of SLC22A13 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 8:127,905,478...127,914,897
Ensembl chr 8:127,909,147...127,912,860
|
|
G |
Mad2l1 |
mitotic arrest deficient 2 like 1 |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of MAD2L1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 4:97,530,993...97,543,179
Ensembl chr 4:97,531,083...97,537,086
|
|
G |
Maf1 |
MAF1 homolog, negative regulator of RNA polymerase III |
multiple interactions |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Sirolimus] results in decreased degradation of MAF1 protein; Cycloheximide inhibits the reaction [Sirolimus results in increased expression of MAF1 protein]; Sirolimus results in increased expression of and results in decreased phosphorylation of MAF1 protein |
CTD |
PMID:31645432 |
|
NCBI chr 7:117,417,643...117,420,722
Ensembl chr 7:117,417,687...117,420,719
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
multiple interactions |
ISO |
[Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form |
CTD |
PMID:21742779 |
|
NCBI chr 3:150,801,289...150,802,935
Ensembl chr 3:150,801,289...150,802,935
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression increases lipidation multiple interactions affects metabolic processing affects localization |
ISO EXP |
Sirolimus results in increased expression of MAP1LC3B mRNA; Sirolimus results in increased expression of MAP1LC3B protein; Sirolimus results in increased expression of MAP1LC3B protein modified form Sirolimus results in increased lipidation of MAP1LC3B protein Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of and results in increased lipidation of MAP1LC3B protein] CD38 gene mutant form promotes the reaction [Sirolimus results in increased expression of MAP1LC3B protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in decreased expression of MAP1LC3B protein]; Sirolimus promotes the reaction [Tunicamycin results in increased lipidation of MAP1LC3B protein] Sirolimus affects the metabolism of MAP1LC3B protein Sirolimus results in increased expression of MAP1LC3B mRNA; Sirolimus results in increased expression of MAP1LC3B protein modified form 3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP1LC3B protein modified form]; saikosaponin inhibits the reaction [Sirolimus results in increased cleavage of MAP1LC3B protein]; Sirolimus inhibits the reaction [saikosaponin results in decreased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of MAP1LC3B protein]]; Sirolimus results in increased expression of and results in increased cleavage of MAP1LC3B protein Sirolimus affects the localization of MAP1LC3B protein |
CTD |
PMID:18640276 PMID:19815708 PMID:21212465 PMID:21681844 PMID:23680031 PMID:24445604 PMID:25884947 PMID:27107786 PMID:29128638 PMID:29518472 PMID:29793971 PMID:30338810 PMID:30555576 PMID:30611790 PMID:31676321 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions increases expression |
EXP |
3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP2 protein]; Chloroquine inhibits the reaction [Sirolimus results in increased expression of MAP2 protein] |
CTD |
PMID:26676567 |
|
NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO EXP |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MAP2K1 protein; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K1 protein Sirolimus inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:12411397 PMID:15767555 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K2 protein |
CTD |
PMID:15767555 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions affects phosphorylation increases phosphorylation decreases phosphorylation |
ISO EXP |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]; Arsenic Trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK1 protein modified form] Sirolimus affects the phosphorylation of MAPK1 protein Sirolimus inhibits the reaction [[IGF1 protein co-treated with U 0126] promotes the reaction [Isoflurane results in decreased phosphorylation of MAPK1 protein]] [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein] Sirolimus results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:15767555 PMID:16255777 PMID:18374093 PMID:19151764 PMID:20936651 PMID:21984483 PMID:22363816 PMID:24392034 PMID:25597859 PMID:25758096 PMID:30905858 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions affects phosphorylation increases phosphorylation decreases phosphorylation |
ISO EXP |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK3 protein modified form] Sirolimus affects the phosphorylation of MAPK3 protein Sirolimus results in decreased phosphorylation of MAPK3 protein [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK3 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15767555 PMID:16255777 PMID:16391472 PMID:18374093 PMID:19151764 PMID:20936651 PMID:21984483 PMID:22363816 PMID:24392034 PMID:25758096 PMID:30905858 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased phosphorylation of MAPK8 protein; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:15767555 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mbnl2 |
muscleblind-like splicing regulator 2 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of MBNL2 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr15:105,640,097...105,797,933
Ensembl chr15:105,640,097...105,797,932
|
|
G |
Mbp |
myelin basic protein |
increases expression |
ISO |
Sirolimus results in increased expression of MBP protein |
CTD |
PMID:20739560 |
|
NCBI chr18:79,326,738...79,437,310
Ensembl chr18:79,326,738...79,437,310
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MCL1 protein; [Sirolimus co-treated with arsenic trioxide] results in decreased expression of MCL1 protein |
CTD |
PMID:15767555 PMID:25758096 |
|
NCBI chr 2:197,786,212...197,788,992
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM2 mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr 4:120,825,699...120,840,221
Ensembl chr 4:120,825,699...120,840,111
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM7 mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr12:19,306,615...19,313,877
Ensembl chr12:19,306,607...19,314,016
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions decreases expression |
ISO |
EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein]; Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]; Sirolimus promotes the reaction [TP73 protein binds to MDM2 promoter] |
CTD |
PMID:15625077 PMID:19560264 PMID:21245298 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mir122 |
microRNA 122 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR122 mRNA] |
CTD |
PMID:23920219 |
|
NCBI chr18:60,755,285...60,755,369
|
|
G |
Mir132 |
microRNA 132 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR132 mRNA] |
CTD |
PMID:23920219 |
|
NCBI chr10:62,014,995...62,015,095
Ensembl chr10:62,014,995...62,015,095
|
|
G |
Mir146a |
microRNA 146a |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR146A mRNA] |
CTD |
PMID:30619488 |
|
NCBI chr10:28,962,476...28,962,570
Ensembl chr10:28,962,476...28,962,570
|
|
G |
Mir151 |
microRNA 151 |
multiple interactions |
ISO |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR151 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 7:114,485,547...114,485,643
|
|
G |
Mir181a2 |
microRNA 181a-2 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of MIR181A2 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 3:23,150,352...23,150,468
Ensembl chr 3:23,150,352...23,150,468
|
|
G |
Mir190 |
microRNA 190 |
multiple interactions |
ISO |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR190A mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 8:73,030,047...73,030,131
Ensembl chr 8:73,030,047...73,030,131
|
|
G |
Mir212 |
microRNA 212 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR212 mRNA] |
CTD |
PMID:23920219 |
|
NCBI chr10:62,014,702...62,014,812
Ensembl chr10:62,014,702...62,014,812
|
|
G |
Mir324 |
microRNA 324 |
multiple interactions |
ISO |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR324 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr10:56,621,126...56,621,208
Ensembl chr10:56,621,124...56,621,212
|
|
G |
Mir330 |
microRNA 330 |
multiple interactions |
ISO |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MIR330 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr 1:80,092,681...80,092,777
Ensembl chr 1:80,092,681...80,092,777
|
|
G |
Mir433 |
microRNA 433 |
multiple interactions |
ISO |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR433 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 6:133,712,334...133,712,426
Ensembl chr 6:133,712,334...133,712,426
|
|
G |
Mir503 |
microRNA 503 |
multiple interactions |
ISO |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR503 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr X:158,148,476...158,148,546
Ensembl chr X:158,148,476...158,148,546
|
|
G |
Mir760 |
microRNA 760 |
multiple interactions |
ISO |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR760 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 2:225,873,354...225,873,433
Ensembl chr 2:225,873,354...225,873,433
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression affects expression multiple interactions |
ISO EXP |
Sirolimus results in decreased expression of MKI67 protein Sirolimus affects the expression of MKI67 mRNA [ABT-737 co-treated with Sirolimus] results in decreased expression of MKI67 protein |
CTD |
PMID:19773376 PMID:24971338 |
|
NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
|
|
G |
Mlst8 |
MTOR associated protein, LST8 homolog |
multiple interactions |
ISO |
Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein] |
CTD |
PMID:19505958 |
|
NCBI chr10:13,839,250...13,845,001
Ensembl chr10:13,839,250...13,845,001
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases secretion increases expression |
ISO |
Sirolimus results in increased secretion of MMP1 protein Sirolimus results in increased expression of MMP1 mRNA |
CTD |
PMID:21742783 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Thioacetamide results in increased activity of MMP2 protein] |
CTD |
PMID:17050028 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression |
EXP |
Sirolimus results in decreased expression of MMP9 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpz |
myelin protein zero |
increases expression |
ISO |
Sirolimus results in increased expression of MPZ protein |
CTD |
PMID:20739560 |
|
NCBI chr13:89,524,204...89,530,070
Ensembl chr13:89,524,329...89,530,068
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of MSR1 mRNA |
CTD |
PMID:17016853 |
|
NCBI chr16:56,817,714...56,900,025
Ensembl chr16:56,813,791...56,900,052
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions increases expression decreases expression decreases phosphorylation increases phosphorylation decreases activity increases activity |
ISO EXP |
[Oxygen deficiency co-treated with Sirolimus] results in decreased expression of MTOR protein; [Sirolimus co-treated with Photosensitizing Agents] affects the phosphorylation of MTOR protein; [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form; [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of DDIT3 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of PKM protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of TP53 protein; [Sirolimus results in decreased activity of MTOR protein] which results in increased phosphorylation of GSK3B protein; [Sirolimus results in decreased activity of MTOR protein] which results in increased susceptibility to afimoxifene; [Sirolimus results in decreased activity of MTOR protein] which results in increased susceptibility to Fulvestrant; [Sirolimus results in decreased phosphorylation of MTOR protein] which results in decreased chemical synthesis of Reactive Oxygen Species; MTOR protein inhibits the reaction [Sirolimus results in decreased activity of RPS6KB2 protein]; Sirolimus inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of MTOR mRNA]; Sirolimus inhibits the reaction [Palmitic Acid results in increased activity of MTOR protein]; Sirolimus inhibits the reaction [puerarin results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Serotonin results in increased activity of MTOR protein]; Sirolimus promotes the reaction [Cisplatin results in decreased phosphorylation of MTOR protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]; Sirolimus results in decreased phosphorylation of and results in increased expression of MTOR protein; sodium arsenite promotes the reaction [Sirolimus results in decreased expression of MTOR protein] Sirolimus results in increased expression of MTOR protein modified form Sirolimus results in decreased expression of MTOR protein; Sirolimus results in decreased expression of MTOR protein modified form Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,2',3,5',6-pentachlorobiphenyl results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Paraquat results in increased phosphorylation of MTOR protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]] Sirolimus results in increased expression of MTOR mRNA Sirolimus results in increased phosphorylation of MTOR protein Sirolimus results in increased activity of MTOR protein [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol affects the susceptibility to Lipopolysaccharides]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased susceptibility to Resveratrol; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Dronabinol results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [MTOR protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of MTOR protein] Sirolimus results in decreased expression of MTOR mRNA; Sirolimus results in decreased expression of MTOR protein; Sirolimus results in decreased expression of MTOR protein modified form [Sirolimus results in decreased activity of MTOR protein] which results in decreased activity of RPS6KB1 protein; Sirolimus results in decreased activity of MTOR protein |
CTD |
PMID:11602639 PMID:12087098 PMID:14673156 PMID:15050414 PMID:15782132 PMID:15919668 PMID:17623046 PMID:17908691 PMID:17968710 PMID:17996122 PMID:18058806 PMID:18381446 PMID:18640276 PMID:18776922 PMID:19016759 PMID:19125612 PMID:19151764 PMID:19505958 PMID:19567381 PMID:19698219 PMID:19815708 PMID:20169165 PMID:20368307 PMID:20680277 PMID:20682991 PMID:21168265 PMID:21187475 PMID:21321189 PMID:21450334 PMID:21742779 PMID:21898527 PMID:22069489 PMID:22363816 PMID:22561310 PMID:22574221 PMID:23111315 PMID:23363784 PMID:23958494 PMID:24971338 PMID:25045214 PMID:25576684 PMID:25884947 PMID:25940091 PMID:26201060 PMID:26282490 PMID:26648565 PMID:27107786 PMID:27133527 PMID:27324791 PMID:27796870 PMID:28342888 PMID:28888487 PMID:29518472 PMID:30132043 PMID:30236763 PMID:30555576 PMID:31051157 PMID:31499194 PMID:32044396 PMID:32329240 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Mturn |
maturin, neural progenitor differentiation regulator homolog |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of MTURN mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 4:84,854,341...84,875,300
Ensembl chr 4:84,854,386...84,871,757
|
|
G |
Mybl2 |
MYB proto-oncogene like 2 |
multiple interactions |
ISO |
[TGFB1 protein co-treated with Sirolimus] results in decreased expression of MYBL2 protein |
CTD |
PMID:12417722 |
|
NCBI chr 3:159,421,638...159,450,087
Ensembl chr 3:159,421,671...159,450,086
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[(+)-JQ1 compound co-treated with Sirolimus] results in decreased expression of MYC protein; [(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of MYC mRNA; [Sirolimus co-treated with letrozole] results in decreased expression of MYC protein |
CTD |
PMID:20054642 PMID:25307878 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Myf5 |
myogenic factor 5 |
decreases expression |
ISO |
Sirolimus results in decreased expression of MYF5 protein |
CTD |
PMID:30905858 |
|
NCBI chr 7:49,729,533...49,732,974
Ensembl chr 7:49,729,533...49,732,764
|
|
G |
Myh11 |
myosin heavy chain 11 |
multiple interactions increases expression |
ISO |
[Sirolimus co-treated with IGF1 protein] results in increased expression of MYH11 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of MYH11 protein Sirolimus results in increased expression of MYH11 protein |
CTD |
PMID:17908691 |
|
NCBI chr10:764,421...859,184
Ensembl chr10:764,421...859,184
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]] |
CTD |
PMID:25045214 |
|
NCBI chr15:33,605,769...33,657,761
Ensembl chr15:33,634,422...33,656,089
|
|
G |
Mylk |
myosin light chain kinase |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr11:69,013,060...69,260,039
Ensembl chr11:69,013,050...69,223,158
|
|
G |
Myod1 |
myogenic differentiation 1 |
affects expression |
ISO |
Sirolimus affects the expression of MYOD1 protein |
CTD |
PMID:30905858 |
|
NCBI chr 1:102,396,538...102,399,248
Ensembl chr 1:102,396,538...102,399,248
|
|
G |
Myof |
myoferlin |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYOF mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 1:256,585,410...256,734,727
Ensembl chr 1:256,585,410...256,734,730
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
decreases expression |
ISO |
Sirolimus results in decreased expression of NAIP mRNA |
CTD |
PMID:9836529 |
|
NCBI chr 2:30,377,505...30,418,578
|
|
G |
Nanog |
Nanog homeobox |
increases expression |
ISO |
Sirolimus results in increased expression of NANOG mRNA |
CTD |
PMID:21681844 |
|
NCBI chr 4:155,531,906...155,539,268
Ensembl chr 4:155,531,906...155,539,268
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions decreases expression |
EXP |
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF1 protein] Sirolimus results in decreased expression of NCF1 protein |
CTD |
PMID:21195169 |
|
NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
decreases expression multiple interactions |
EXP |
Sirolimus results in decreased expression of NCF2 protein Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF2 protein] |
CTD |
PMID:21195169 |
|
NCBI chr13:70,226,441...70,259,019
Ensembl chr13:70,226,647...70,257,576
|
|
G |
Ncf4 |
neutrophil cytosolic factor 4 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF4 protein] |
CTD |
PMID:21195169 |
|
NCBI chr 7:119,481,711...119,499,426
Ensembl chr 7:119,482,272...119,499,425
|
|
G |
Ndc80 |
NDC80 kinetochore complex component |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of NDC80 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 9:119,837,857...119,871,435
Ensembl chr 9:119,839,016...119,871,382
|
|
G |
Nek2 |
NIMA-related kinase 2 |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of NEK2 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr13:110,511,546...110,524,750
Ensembl chr13:110,511,668...110,522,769
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions increases activity |
EXP ISO |
NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]]; NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]]; NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein]]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of NFE2L2 mRNA]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of NFE2L2 protein] Sirolimus results in increased activity of NFE2L2 protein |
CTD |
PMID:28624451 PMID:30203046 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Doxorubicin results in increased activity of NFKB1 protein] |
CTD |
PMID:15571967 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
Sirolimus inhibits the reaction [Doxorubicin results in increased degradation of and results in decreased expression of NFKBIA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] Sirolimus inhibits the reaction [Isoproterenol results in increased degradation of NFKBIA protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased phosphorylation of NFKBIA protein] [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:15571967 PMID:18789402 PMID:22363816 PMID:23211629 PMID:25045214 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions decreases expression |
ISO |
Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein] Sirolimus results in decreased expression of NLRP3 protein |
CTD |
PMID:30205151 PMID:32645460 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of NME1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr10:81,657,152...81,666,542
Ensembl chr10:81,657,153...81,666,523
|
|
G |
Nmu |
neuromedin U |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of NMU mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr14:34,353,683...34,381,968
Ensembl chr14:34,354,503...34,381,828
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]] Sirolimus inhibits the reaction [Pilocarpine results in increased expression of NOS2 mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of NOS2 protein] |
CTD |
PMID:22363816 PMID:23211629 PMID:31499194 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases phosphorylation decreases expression |
ISO |
Aspirin inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein] Sirolimus results in increased phosphorylation of NOS3 protein Sirolimus results in decreased expression of NOS3 mRNA; Sirolimus results in decreased expression of NOS3 protein |
CTD |
PMID:17261647 PMID:19520256 PMID:19815708 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Notch1 |
notch receptor 1 |
affects expression |
EXP |
Sirolimus affects the expression of NOTCH1 protein |
CTD |
PMID:26676567 |
|
NCBI chr 3:3,905,562...3,951,015
Ensembl chr 3:3,905,453...3,951,025
|
|
G |
Nphs2 |
NPHS2 stomatin family member, podocin |
affects expression |
EXP |
Sirolimus affects the expression of NPHS2 protein |
CTD |
PMID:19671594 |
|
NCBI chr13:73,929,136...73,941,522
Ensembl chr13:73,929,136...73,941,522
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]; Sirolimus inhibits the reaction [rosiglitazone results in increased expression of NPPA mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]] |
CTD |
PMID:19397913 PMID:25045214 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]] |
CTD |
PMID:25045214 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
affects expression |
ISO |
Sirolimus affects the expression of NR1H3 protein |
CTD |
PMID:17016853 |
|
NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of NR1H4 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
increases activity |
ISO |
Sirolimus results in increased activity of NR3C1 protein |
CTD |
PMID:15697228 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Ethanol results in decreased expression of NR5A1 protein] |
CTD |
PMID:29524503 |
|
NCBI chr 3:22,998,900...23,020,441
Ensembl chr 3:22,999,616...23,020,441
|
|
G |
Nxt1 |
nuclear transport factor 2-like export factor 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of NXT1 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr 3:142,993,658...142,996,580
Ensembl chr 3:142,993,658...142,996,578
|
|
G |
Ogn |
osteoglycin |
increases expression |
EXP |
Sirolimus results in increased expression of OGN mRNA |
CTD |
PMID:21865292 |
|
NCBI chr17:14,607,442...14,628,274
Ensembl chr17:15,447,716...15,467,359 Ensembl chr17:15,447,716...15,467,359
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
affects expression |
ISO |
Sirolimus affects the expression of OLR1 protein |
CTD |
PMID:17016853 |
|
NCBI chr 4:163,239,853...163,261,937
Ensembl chr 4:163,239,849...163,261,958
|
|
G |
Optn |
optineurin |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of OPTN protein] |
CTD |
PMID:25884947 |
|
NCBI chr17:77,167,700...77,218,374
Ensembl chr17:77,167,740...77,218,389
|
|
G |
Oxa1l |
OXA1L, mitochondrial inner membrane protein |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of OXA1L mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr15:33,004,957...33,012,584
Ensembl chr15:33,004,133...33,012,575
|
|
G |
Pabpc1 |
poly(A) binding protein, cytoplasmic 1 |
multiple interactions decreases expression |
ISO |
Sirolimus inhibits the reaction [EIF4G1 protein binds to PABPC1 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to PABPC1 mRNA] Sirolimus results in decreased expression of PABPC1 protein |
CTD |
PMID:25940091 |
|
NCBI chr 7:75,409,581...75,421,874
Ensembl chr 7:75,409,581...75,422,268
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases expression increases cleavage |
ISO EXP |
ATG5 protein affects the reaction [Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]]; Sirolimus inhibits the reaction [Ethanol results in increased cleavage of PARP1 protein]; Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein] Sirolimus promotes the reaction [Cadmium results in increased cleavage of PARP1 protein] [Sirolimus co-treated with Resveratrol] results in increased cleavage of PARP1 protein; TSC2 protein inhibits the reaction [[Sirolimus co-treated with Resveratrol] results in increased cleavage of PARP1 protein] Sirolimus results in increased expression of PARP1 protein modified form Sirolimus results in increased cleavage of PARP1 protein |
CTD |
PMID:19682553 PMID:21410490 PMID:24304514 PMID:25307878 PMID:26825372 PMID:29111403 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pax8 |
paired box 8 |
multiple interactions |
ISO |
Sirolimus promotes the reaction [TP73 protein affects the activity of PAX8 protein] |
CTD |
PMID:21245298 |
|
NCBI chr 3:1,527,316...1,586,019
Ensembl chr 3:1,527,279...1,584,946
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
EXP |
[troglitazone co-treated with Sirolimus] results in decreased expression of PCK1 mRNA |
CTD |
PMID:10446394 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions decreases expression |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of PCNA mRNA Sirolimus inhibits the reaction [IL2 protein results in increased expression of PCNA mRNA] Sirolimus results in decreased expression of PCNA protein |
CTD |
PMID:9151781 PMID:11355896 PMID:19016759 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pdcd4 |
programmed cell death 4 |
multiple interactions increases stability increases expression |
ISO EXP |
[resveratrol co-treated with Sirolimus] results in increased stability of PDCD4 protein; Sirolimus promotes the reaction [Tretinoin results in increased expression of PDCD4 protein] Sirolimus results in increased stability of PDCD4 protein resveratrol inhibits the reaction [Sirolimus results in increased stability of PDCD4 protein] [Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein; PDCD4 mutant form inhibits the reaction [Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in decreased expression of PDCD4 mRNA]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in decreased expression of PDCD4 protein]; TSC2 gene mutant form promotes the reaction [[Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein] Sirolimus results in increased expression of PDCD4 protein Sirolimus results in increased expression of PDCD4 mRNA; Sirolimus results in increased expression of PDCD4 protein |
CTD |
PMID:17259349 PMID:24304514 PMID:24356939 PMID:26369790 |
|
NCBI chr 1:274,616,625...274,648,204
Ensembl chr 1:274,625,224...274,648,204
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein] |
CTD |
PMID:15919668 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
decreases response to substance increases activity multiple interactions |
ISO |
Sirolimus results in decreased susceptibility to PIK3CA protein Sirolimus results in increased activity of PIK3CA protein Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CXCL8 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of PPP2R1B mRNA]; Wortmannin inhibits the reaction [Sirolimus results in increased activity of PIK3CA protein] |
CTD |
PMID:10373522 PMID:16227402 PMID:27542212 |
|
NCBI chr 2:118,831,350...118,861,456
Ensembl chr 2:118,831,350...118,861,454
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
Sirolimus promotes the reaction [IRS1 protein binds to PIK3R1 protein] |
CTD |
PMID:17908691 |
|
NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
|
|
G |
Pim1 |
Pim-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of PIM1 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr20:8,165,423...8,169,557
Ensembl chr20:8,165,307...8,169,555
|
|
G |
Pkm |
pyruvate kinase M1/2 |
multiple interactions |
ISO |
[Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of PKM protein |
CTD |
PMID:22574221 |
|
NCBI chr 8:64,480,963...64,502,957
Ensembl chr 8:64,481,172...64,502,722
|
|
G |
Pkp4 |
plakophilin 4 |
increases expression |
EXP |
Sirolimus results in increased expression of PKP4 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 3:45,211,097...45,414,524
Ensembl chr 3:45,277,348...45,414,613
|
|
G |
Plcl1 |
phospholipase C-like 1 |
increases expression |
ISO |
Sirolimus results in increased expression of PLCL1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 9:62,016,112...62,349,244
Ensembl chr 9:62,291,405...62,349,309
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
[[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein |
CTD |
PMID:20686837 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Pml |
PML nuclear body scaffold |
increases expression increases localization decreases response to substance |
ISO |
Sirolimus results in increased expression of PML protein Sirolimus results in increased localization of PML protein PML protein results in decreased susceptibility to Sirolimus |
CTD |
PMID:23440206 |
|
NCBI chr 8:63,002,515...63,034,310
Ensembl chr 8:63,004,870...63,034,226
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
increases metabolic processing |
ISO |
Sirolimus results in increased metabolism of PMP22 protein mutant form |
CTD |
PMID:20739560 |
|
NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
increases expression |
ISO |
Sirolimus results in increased expression of PNPLA2 mRNA; Sirolimus results in increased expression of PNPLA2 protein |
CTD |
PMID:20068142 |
|
NCBI chr 1:214,434,638...214,439,720
Ensembl chr 1:214,434,626...214,439,720
|
|
G |
Pnrc1 |
proline-rich nuclear receptor coactivator 1 |
increases expression |
ISO |
Sirolimus results in increased expression of PNRC1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 5:48,501,472...48,504,511
Ensembl chr 5:48,501,472...48,504,511
|
|
G |
Pold2 |
DNA polymerase delta 2, accessory subunit |
decreases expression |
ISO |
Sirolimus results in decreased expression of POLD2 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr14:86,111,416...86,117,578
Ensembl chr14:86,111,294...86,117,578
|
|
G |
Polr1h |
RNA polymerase I subunit H |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of POLR1H mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr20:2,088,518...2,092,436
Ensembl chr20:2,088,533...2,092,436
|
|
G |
Postn |
periostin |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] |
CTD |
PMID:15121739 |
|
NCBI chr 2:143,656,820...143,688,087
Ensembl chr 2:143,656,793...143,688,087
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
increases expression |
ISO |
Sirolimus results in increased expression of POU5F1 mRNA; Sirolimus results in increased expression of POU5F1 protein |
CTD |
PMID:21681844 |
|
NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]] |
CTD |
PMID:25045214 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein] |
CTD |
PMID:24898257 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects expression decreases expression multiple interactions |
ISO |
Sirolimus affects the expression of PPARG protein Sirolimus results in decreased expression of PPARG mRNA [Sirolimus co-treated with Cyclosporine] results in decreased expression of PPARG protein; [Sirolimus co-treated with Tacrolimus] results in increased expression of PPARG protein |
CTD |
PMID:15358118 PMID:17016853 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]] Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:25045214 PMID:31499194 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ppl |
periplakin |
increases expression |
EXP |
Sirolimus results in increased expression of PPL mRNA |
CTD |
PMID:21865292 |
|
NCBI chr10:10,644,572...10,690,223
Ensembl chr10:10,644,572...10,690,223
|
|
G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B mRNA]; Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B protein] |
CTD |
PMID:17209049 |
|
NCBI chr10:86,303,727...86,312,770
Ensembl chr10:86,303,727...86,312,762
|
|
G |
Ppp2r1b |
protein phosphatase 2 scaffold subunit A beta |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of PPP2R1B mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr 8:55,279,278...55,311,768
Ensembl chr 8:55,279,373...55,301,320
|
|
G |
Prcp |
prolylcarboxypeptidase |
increases expression |
EXP |
Sirolimus results in increased expression of PRCP mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:157,701,089...157,750,177
Ensembl chr 1:157,701,089...157,750,169
|
|
G |
Prf1 |
perforin 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of PRF1 protein |
CTD |
PMID:16477233 |
|
NCBI chr20:30,915,294...30,920,804
Ensembl chr20:30,915,213...30,921,382
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Cadmium Chloride results in decreased phosphorylation of PRKAA1 protein] |
CTD |
PMID:21195169 |
|
NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Estradiol results in increased phosphorylation of PRKCA protein] |
CTD |
PMID:23000059 |
|
NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
|
|
G |
Prkcd |
protein kinase C, delta |
affects localization multiple interactions decreases phosphorylation |
ISO |
Sirolimus affects the localization of PRKCD protein sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of PRKCD protein] |
CTD |
PMID:20082316 |
|
NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
|
|
G |
Prkcg |
protein kinase C, gamma |
increases degradation multiple interactions |
ISO |
Sirolimus results in increased degradation of PRKCG protein mutant form Sirolimus inhibits the reaction [PRKCG protein mutant form binds to PRKCG protein mutant form] |
CTD |
PMID:20398063 |
|
NCBI chr 1:64,407,098...64,433,698
Ensembl chr 1:64,407,114...64,433,636
|
|
G |
Prkch |
protein kinase C, eta |
decreases response to substance multiple interactions |
ISO |
PRKCH results in decreased susceptibility to Sirolimus [Tetradecanoylphorbol Acetate results in increased activity of PRKCH protein] inhibits the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein] |
CTD |
PMID:16832347 |
|
NCBI chr 6:96,479,243...96,677,368
Ensembl chr 6:96,479,430...96,676,225
|
|
G |
Prlr |
prolactin receptor |
decreases expression |
EXP |
Sirolimus results in decreased expression of PRLR mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 2:60,131,410...60,325,686
Ensembl chr 2:60,131,776...60,325,692
|
|
G |
Psma1 |
proteasome 20S subunit alpha 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of PSMA1 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr 1:183,733,567...183,744,586
Ensembl chr 1:183,733,567...183,744,586
|
|
G |
Psma4 |
proteasome 20S subunit alpha 4 |
decreases expression |
ISO |
Sirolimus results in decreased expression of PSMA4 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr 8:59,532,456...59,539,916
Ensembl chr 8:59,532,389...59,539,920
|
|
G |
Psmd11 |
proteasome 26S subunit, non-ATPase 11 |
decreases expression |
ISO |
Sirolimus results in decreased expression of PSMD11 mRNA; Sirolimus results in decreased expression of PSMD11 protein |
CTD |
PMID:15782132 |
|
NCBI chr10:67,810,655...67,857,562
Ensembl chr10:67,810,655...67,857,223
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions decreases expression decreases response to substance |
ISO EXP |
[Decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of PTEN mRNA; Sirolimus inhibits the reaction [TNF protein results in decreased expression of PTEN protein] Sirolimus inhibits the reaction [Cadmium Chloride results in decreased expression of PTEN protein] Sirolimus results in decreased expression of PTEN protein PTEN protein results in decreased susceptibility to Sirolimus |
CTD |
PMID:18303120 PMID:18622747 PMID:19625624 PMID:21195169 PMID:31676321 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein] |
CTD |
PMID:20335389 |
|
NCBI chr19:24,799,422...24,803,373
Ensembl chr19:24,800,072...24,803,373
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions affects expression |
ISO EXP |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]] Sirolimus affects the expression of PTGS2 mRNA Sirolimus inhibits the reaction [Pilocarpine results in increased expression of PTGS2 mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of PTGS2 protein] |
CTD |
PMID:22363816 PMID:23211629 PMID:24971338 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
decreases phosphorylation |
ISO |
Sirolimus results in decreased phosphorylation of PTK2 protein |
CTD |
PMID:19922502 |
|
NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
|
|
G |
Ptpn5 |
protein tyrosine phosphatase, non-receptor type 5 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein] |
CTD |
PMID:17623046 |
|
NCBI chr 1:103,197,918...103,258,309
Ensembl chr 1:103,197,915...103,256,823
|
|
G |
Ptprc |
protein tyrosine phosphatase, receptor type, C |
increases expression |
ISO |
Sirolimus results in increased expression of PTPRC mRNA |
CTD |
PMID:11355896 |
|
NCBI chr13:55,061,561...55,174,150
Ensembl chr13:55,061,562...55,173,692
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of PTTG1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr10:29,014,332...29,026,088
Ensembl chr10:29,020,049...29,026,002
|
|
G |
Rac1 |
Rac family small GTPase 1 |
decreases expression multiple interactions |
EXP |
Sirolimus results in decreased expression of RAC1 protein Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of RAC1 protein] |
CTD |
PMID:21195169 |
|
NCBI chr12:13,090,316...13,111,841
Ensembl chr12:13,090,172...13,111,873
|
|
G |
Rad51 |
RAD51 recombinase |
multiple interactions |
ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of RAD51 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of RAF1 protein |
CTD |
PMID:15767555 |
|
NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; [Sirolimus co-treated with Letrozole] results in decreased expression of RB1 protein; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [tanespimycin co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein] Sirolimus results in decreased phosphorylation of RB1 protein [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [KITL protein results in increased phosphorylation of RB1 protein] |
CTD |
PMID:7532117 PMID:8419408 PMID:10373522 PMID:10849422 PMID:12393642 PMID:12417722 PMID:12565877 PMID:14979923 PMID:15753396 PMID:15778701 PMID:17121904 PMID:17700525 PMID:20054642 PMID:21528311 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
multiple interactions |
ISO |
[TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein] |
CTD |
PMID:12417722 |
|
NCBI chr 3:153,263,692...153,321,351
Ensembl chr 3:153,263,692...153,321,352
|
|
G |
Rbl2 |
RB transcriptional corepressor like 2 |
multiple interactions |
ISO |
[TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RBL2 protein] |
CTD |
PMID:10373522 PMID:12417722 |
|
NCBI chr19:17,300,088...17,346,865
Ensembl chr19:17,300,089...17,346,808
|
|
G |
Rcan1 |
regulator of calcineurin 1 |
multiple interactions |
ISO |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of RCAN1 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr11:32,539,689...32,620,274
Ensembl chr11:32,539,683...32,550,539
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
Sirolimus inhibits the reaction [Doxorubicin results in increased activity of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] Sirolimus inhibits the reaction [Isoproterenol affects the localization of RELA protein]; Sirolimus inhibits the reaction [Zearalenone results in increased phosphorylation of and affects the localization of RELA protein] [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] |
CTD |
PMID:15571967 PMID:18789402 PMID:22003094 PMID:22363816 PMID:25045214 PMID:31586597 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Ren |
renin |
increases expression |
EXP |
Sirolimus results in increased expression of REN mRNA |
CTD |
PMID:21865292 |
|
NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
|
|
G |
Rest |
RE1-silencing transcription factor |
multiple interactions |
ISO |
Sirolimus promotes the reaction [TP73 protein affects the activity of REST protein] |
CTD |
PMID:21245298 |
|
NCBI chr14:33,131,985...33,152,019
Ensembl chr14:33,134,511...33,164,141
|
|
G |
Rictor |
RPTOR independent companion of MTOR, complex 2 |
decreases expression |
ISO |
Sirolimus results in decreased expression of RICTOR protein |
CTD |
PMID:18776922 |
|
NCBI chr 2:56,013,898...56,105,818
Ensembl chr 2:56,052,643...56,101,803
|
|
G |
Rpl32 |
ribosomal protein L32 |
multiple interactions decreases expression |
ISO |
LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPL32 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPL32 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPL32 mRNA] |
CTD |
PMID:25940091 |
|
NCBI chr 4:147,715,480...147,719,044
Ensembl chr 6:145,777,318...145,777,767 Ensembl chr 4:145,777,318...145,777,767
|
|
G |
Rps20 |
ribosomal protein S20 |
multiple interactions decreases expression |
ISO |
LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS20 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS20 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS20 mRNA] |
CTD |
PMID:25940091 |
|
NCBI chr 5:16,706,052...16,707,214
Ensembl chr 5:16,706,082...16,706,909
|
|
G |
Rps27l |
ribosomal protein S27-like |
multiple interactions |
ISO |
Sirolimus promotes the reaction [TP73 protein binds to RPS27L promoter] |
CTD |
PMID:21245298 |
|
NCBI chr 8:72,741,155...72,746,090
Ensembl chr 8:72,741,155...72,746,090
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions decreases phosphorylation increases phosphorylation decreases expression |
ISO EXP |
[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6 protein; [Tetradecanoylphorbol Acetate results in increased activity of PRKCH protein] inhibits the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS6 protein]; Sirolimus inhibits the reaction [CXCL8 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS6 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Testosterone results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus promotes the reaction [LARP1 protein binds to RPS6 mRNA]; TSC2 gene mutant form promotes the reaction [[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein]; TSC2 gene mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein] [resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein Sirolimus results in increased phosphorylation of RPS6 protein [Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RPS6 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]] |
CTD |
PMID:1614535 PMID:10373522 PMID:12939469 PMID:14502240 PMID:15297429 PMID:15778701 PMID:16832347 PMID:17121904 PMID:17606477 PMID:17908691 PMID:19478560 PMID:19625624 PMID:20038814 PMID:20068142 PMID:20169165 PMID:20863555 PMID:21036700 PMID:21212465 PMID:21245298 PMID:21450334 PMID:22069489 PMID:23363784 PMID:23440206 PMID:24304514 PMID:24375594 PMID:24386346 PMID:24392034 PMID:25940091 PMID:26621329 PMID:27255535 PMID:28342888 PMID:28574600 PMID:28790194 PMID:29793971 PMID:30619488 PMID:30687088 PMID:31051157 PMID:31676321 |
|
NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
|
|
G |
Rps6ka1 |
ribosomal protein S6 kinase A1 |
increases phosphorylation multiple interactions affects localization |
ISO EXP |
Sirolimus results in increased phosphorylation of RPS6KA1 protein Sirolimus results in increased phosphorylation of and results in increased activity of RPS6KA1 protein Sirolimus affects the localization of RPS6KA1 protein |
CTD |
PMID:19151764 |
|
NCBI chr 5:152,078,217...152,122,684
Ensembl chr 5:152,078,220...152,122,684
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
affects localization increases phosphorylation |
ISO |
Sirolimus affects the localization of RPS6KA2 protein Sirolimus results in increased phosphorylation of RPS6KA2 protein |
CTD |
PMID:19151764 |
|
NCBI chr 1:53,219,346...53,499,445
Ensembl chr 1:53,360,157...53,499,445
|
|
G |
Rps6ka3 |
ribosomal protein S6 kinase A3 |
affects localization increases phosphorylation |
ISO |
Sirolimus affects the localization of RPS6KA3 protein Sirolimus results in increased phosphorylation of RPS6KA3 protein |
CTD |
PMID:19151764 |
|
NCBI chr X:37,469,736...37,576,055
Ensembl chr X:37,469,937...37,575,624
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions increases expression decreases phosphorylation increases phosphorylation decreases expression decreases activity |
ISO EXP |
[Dexamethasone co-treated with Sirolimus] inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IL6 protein results in increased phosphorylation of RPS6KB1 protein]; [Resveratrol co-treated with Sirolimus] results in increased phosphorylation of RPS6KB1 protein; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in decreased abundance of Superoxides; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased abundance of Nitric Oxide; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased activity of IRS1 protein; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Acetaldehyde results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Orotic Acid results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [oxophenylarsine results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [puerarin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Testosterone results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [sodium arsenite results in decreased phosphorylation of RPS6KB1 protein]; Sirolimus results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6KB1 protein] Sirolimus results in increased expression of RPS6KB1 protein modified form Sirolimus results in increased phosphorylation of RPS6KB1 protein Sirolimus results in decreased expression of RPS6KB1 protein modified form Sirolimus results in decreased phosphorylation of RPS6KB1 protein; Sirolimus results in decreased phosphorylation of S6K protein [Sirolimus co-treated with Resveratrol] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX protein; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID protein; MRK 003 promotes the reaction [Sirolimus results in decreased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Dronabinol results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [MTOR protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Propranolol results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of RPS6KB1 protein modified form]; Sirolimus promotes the reaction [MRK 003 results in decreased activity of RPS6KB1 protein]; Sirolimus promotes the reaction [Resveratrol results in decreased phosphorylation of RPS6KB1 protein] [Sirolimus co-treated with Resveratrol] results in decreased phosphorylation of RPS6KB1 protein; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [Phenylephrine results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [Resveratrol inhibits the reaction [TSC2 protein results in decreased phosphorylation of RPS6KB1 protein]]; Sirolimus inhibits the reaction [Sertraline results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein [Sirolimus results in decreased activity of MTOR protein] which results in decreased activity of RPS6KB1 protein; Sirolimus results in decreased activity of RPS6KB1 protein |
CTD |
PMID:12411397 PMID:14516795 PMID:14673156 PMID:15070696 PMID:15297429 PMID:15782132 PMID:15914125 PMID:15919668 PMID:16183647 PMID:16391472 PMID:16537399 PMID:16962100 PMID:17616671 PMID:17728140 PMID:17908691 PMID:18021293 PMID:18495876 PMID:18622747 PMID:19246562 PMID:19567381 PMID:19625624 PMID:19810018 PMID:19922502 PMID:20169165 PMID:20574048 PMID:20682991 PMID:20880397 PMID:20936651 PMID:21036700 PMID:21168265 PMID:21321189 PMID:21357504 PMID:21544240 PMID:21858812 PMID:21898527 PMID:21933187 PMID:21984483 PMID:22215663 PMID:22574221 PMID:22863860 |